key: cord-0035176-159p181f
authors: Groshong, Steve D.; Tomashefski, Joseph F.; Cool, Carlyne D.
title: Pulmonary Vascular Disease
date: 2008
journal: Dail and Hammar’s Pulmonary Pathology
DOI: 10.1007/978-0-387-68792-6_28
sha: ab5f5e0f4c94fcf175a5b9eb7bec0d266b620cfe
doc_id: 35176
cord_uid: 159p181f

The pulmonary vasculature is an anatomic compartment that is frequently overlooked in the histologic review of lung biopsy samples, other than those obtained specifically to assess pulmonary vascular disease.1 Though often of a nonspecific nature, the histologic pattern of vascular remodeling may at times suggest its underlying pathogenesis and provide clues to the cause of pulmonary hypertension.2 Disproportionately severe vascular pathology may further indicate alternate disease processes, such as congestive heart failure or thromboemboli, contributing to the patient’s overall respiratory condition.

Steve D. Groshong, Joseph F. Tomashefski, Jr., and Cadyne D. Cool

The pulmonary vasculature is an anatomic compartment that is frequently overlooked in the histologic review of lung biopsy samples, other than those obtained specifically to assess pulmonary vascular disease. 1 Though often of a nonspecific nature, the histologic pattern of vascular remodeling may at times suggest its underlying pathogenesis and provide clues to the cause of pulmonary hypertension. 2 Disproportionately severe vascular pathology may further indicate alternate disease processes, such as congestive heart failure or thromboemboli, contributing to the patient's overall respiratory condition.

This chapter discusses pulmonary hypertension, which represents a final common pathway of pulmonary vascular disease. 3 Idiopathic pulmonary arterial hypertension (i.e., primary pulmonary hypertension) serves as a model of vascular reconfiguration formerly designated as "plexogenic arteriopathy.,, 4 The 2003 World Health Organization (WHO) classification of pulmonary hypertension, however, has shifted the primary emphasis from the plexiform lesion (now considered a generic marker of severe pulmonary hypertension) toward an integrated construct that incorporates clinical history, epidemiology, and morphology in the classification schema. s

Other major categories of pulmonary hypertension, including thromboembolic, hypoxic, and pulmonary venous hypertension, are each considered in separate sections that focus on morphologic patterns of recognition and the important underlying conditions that contribute to each category. The broad and complex topic of pulmonary vasculitis is discussed in Chapter 29, which serves as a companion chapter to this chapter.

It is, admittedly, artificial to segregate pulmonary vascular pathology in one or two isolated chapters since blood vessels are involved either primarily or secondarily across the vast spectrum of lung pathology. The reader is therefore liberally referred to other areas of the text where vascular pathology is considered in the context of parenchymal or airway diseases. For example, the 1032 important vascular changes of Langerhans cell histiocytosis, sarcoidosis, and amyloidosis are respectively addressed in Chapters 17, 18, and 21 . Remodeling of the bronchial arteries is an important focus in the section on bronchiectasis in Chapter 5. Vascular malformations predominantly affecting the pediatric population are mainly discussed in Chapter 6, and intralobar sequestration, considered by many an acquired rearrangement of the pulmonary blood supply, is covered in Chapter 7. The topic of vasoformative neoplasms, including hemangiomas, lymphangiomatous proliferations, angiosarcoma, and pulmonary artery sarcoma, is covered in Chapter 40 on mesenchymal tumors. Although pulmonary capillary hemangiomatosis is considered by some to be a neoplastic proliferation, because of its close morphologic and (possibly) pathogenetic associations with pulmonary veno-occlusive disease, this entity is mainly discussed in this chapter.

Diseases of the lung vasculature, notably pulmonary embolism, are also frequently implicated as underlying, immediate, or contributory causes of death. It is a somber reality that fatalities secondary to clinically undiagnosed pulmonary embolism are a major source of medical malpractice claims. The forensic issues related to pulmonary embolism and the topics of air, amniotic fluid, and fat embolism are primarily addressed in Chapter 31 on pulmonary forensic pathology. Other forms of nonthrombotic emboli, such as parasites (Chapter 14) , tumors (Chapter 44), soft tissue (Chapter 31) and pharmaceutical tablet filler materials (Chapter 26), are each primarily discussed in the context of the disease categories in which the emboli arise.

Finally, the reader is encouraged also to review the sections on lung vascular anatomy and histology (Chapter 2) and the various techniques relevant to the study of the pulmonary vasculature (Chapter 1), which serve as fundamental starting points in the morphologic assessment of pulmonary vascular disease.

In the embryonic period (4 to 6 weeks gestational age) the developing circulatory system consists of six pairs of aortic arches that join the dorsal and ventral aortas, which arise from the primitive heart ( Fig. 28.1) . 6 According to classical embryology, the right and left pulmonary arteries are derived mainly from the sixth aortic arches, which are formed by the 36th day of development. 7 The dorsolateral portion of the right sixth aortic arch ultimately disappears; the ventral part persists as the proximal right pulmonary artery. The dorsal portion of the left sixth arch persists as the ductus arteriosus joining the pulmonary artery and aorta, while the ventral left sixth aortic arch becomes the proximal portion of the left main pulmonary artery ( Fig. 28.1 ). Recent evidence, however, suggests that the pulmonary arteries may initially arise from the fourth and later merge with the sixth aortic arch. 6 The right and left pulmonary arteries, by day 50, have joined the vascular plexus that surrounds and infiltrates the lung buds. Small vessels within the lung buds are formed in situ by the process of vasculogenesis. 8 The pulmonary trunk is formed as the aorticopulmonary septum divides the truncus arteriosus into two major channels-the aorta and the pulmonary artery ( Fig. 28.1 ).6 After birth, the ductus arteriosus closes to become the ligamentum arteriosum.

Part of maxillary a.

L. dorsal aorta FIGURE 28.1. Embryologic development of the aortic system and pulmonary arteries. A. A 29-day embryo. Aortic arches joining dorsal and ventral aortas. The sixth aortic arch appears around day 29. B. A 7-week embryo. The pulmonary arteries may initially sprout from arch 4 and become secondarily connected to the sixth arch. The pulmonary trunk evolves from the 1033 Veins A single main pulmonary vein initially arises from the cardiac atrium around the 4th week. The vein rapidly branches into the right and left pulmonary veins, each of which further divides, producing a total of four pulmonary veins. The pulmonary veins connect with the venous plexus around the esophagus and developing lung buds. As the left atrium enlarges, it absorbs, by a process of intussusception, the main and then the right and left branches to just beyond the entry of their main tributaries. In this manner, four separate venous openings are found in the dorsal wall of the left atrium. Even in the adult, small connections persist between the pulmonary and esophageal veins near the lung hilum. During fetal life, the pulmonary veins carry little blood and are largely free of muscle. A continuous smooth muscle coat is only present near term.9

During the embryonic period, transient feeding vessels are thought to extend directly from the dorsal aorta to the developing lung buds, although this concept has been challenged. 8 Persistence of these vascular sprouts may result in aberrant systemic blood supply to the lung. Definitive bronchial arteries, which nourish the bronchi, pleura, and walls of vessels, arise from the aorta in the 9th to 12th week of gestation. 10 In the normal fetus, patent precapillary anastomoses between bronchial and pulmonary circulations are infrequently observed. There is, however, free communications between the two circulations at the capillary level, and both systems drain into the pulmonary veins. 7 ,11 Congenital Vascular Malformations Congenital malformations of the pulmonary vasculature are rare lesions, usually seen in children, and often associated with congenital cardiac anomalies. Two of the more notable conditions in which anomalous lung vessels play a role are the scimitar syndrome (anomalous pulmonary venous return) and intralobar sequestration (aberrant aortic-derived blood supply). The scimitar syndrome is discussed in Chapter 6, and intralobar sequestration is considered in Chapter 7. Other anomalies of the pulmonary vasculature that can contribute to pulmonary hypertension include persistent truncus arteriosus, aorticopulmonary septal defect, and assorted anomalies of pulmonary veins. These exceedingly rare malformations are discussed in the textbook by Wagenvoort and Wagenvoort. 12 Some selected important anomalies of pulmonary vessels are discussed in detail below.

Unilateral absence of a main pulmonary artery is an infrequent congenital anomaly that may present as an isolated lesion or in association with other cardiac or vascular anomalies (combined anomaly) in children or (more frequently) adults. Absence of the left pulmonary artery has been particularly associated with tetralogy of Fallot (e.g., pulmonary stenosis, ventricular septal defect, overriding dextroposed aorta, and right ventricular hypertrophy), while an absent right pulmonary artery more frequently occurs with patent ductus arteriosus.1 3 . 14 The blood supply to the affected lung may derive directly from the aorta as in some cases of absent right pulmonary artery, or from bronchial arteries or an aortic arch vessel in most cases of absent left pulmonary artery and other instances of absent right pulmonary artery. Collateral supply from the coronary arteries has also been described. 15 Patients exhibit respiratory complaints of recurrent pneumonia or, less frequently, hemoptysis. Cardiovascular symptoms depend on whether the lesion is an isolated or a combined anomaly. Patients with an isolated absence of the pulmonary artery may have no cardiovascular symptoms. Approximately 85% of combined anomalies progress to pulmonary hypertension. The most important finding on the plane chest x-ray is ipsilateral pulmonary hypovascularity. Unilateral thrombotic or embolic occlusion of a pulmonary artery is the most difficult lesion to distinguish angiographically from unilateral absence of the pulmonary artery ( Fig. 28. 2) (see also Fig. 28.32) . 16 Within the ipsilateral lung, intrapulmonary arteries may be either normal or exhibit features of pulmonary hypertension, such as medial hypertrophy, intimal fibrosis, or trophic muscular artery is in the position of a normal intraparenchymal pulmonary artery. ( Pleural collateral vessels may be prominent. 14.17.18 The lung on the affected slide is often hypoplastic. 17 ,19 Congenital Pulmonary Stenosis/Atresia and Tetralogy of Fallot: Vascular Remodeling in Low-Flow States Diminution of the pulmonary arterial pulse pressures and blood flow occurs in a variety of congenital cardiac malformations that impede right ventricular outflow, especially pulmonary artery stenosis, pulmonic valve stenosis or atresia, and tetralogy of Fallot. In tetralogy of Fallot, the pulmonary trunk is narrower than the aorta, while the main pulmonary arteries may be normal or hypoplastic. Stenosis of the distal pulmonary trunk and bilateral main pulmonary arteries may be diffuse or localized ( Fig.  28. 3).20 Saccular dilatation may occur distal to strictures. Intraparenchymal pulmonary arteries have a normal anatomic distribution. 8 The most constant finding in the elastic pulmonary arteries of any of these disorders is thinning of the media, often to a marked degree (Fig. 28.4) . 21 In tetralogy of Fallot mural thinning may extend to the level of muscular arteries, which, along with capillaries and pulmonary veins, may be markedly dilated. When mural thinning is extreme, medial muscle may be focally absent. Similar changes have also been described in pulmonic atresia. 22 Medial atrophy and widened vascular lumina tend to be more pronounced in isolated pulmonic stenosis than in tetralogy of Fallot. 21 Other associated findings include intimal fibrosis and thrombotic lesions (including web strictures in lobar, segmental, and/or peripheral branches. (From Goor DA, Lillehei Cw. Congenital malformations of the heart. New York: Grune & Stratton, 1975, with permission from Elsevier. Copyright © 1975.) lesions), which are more frequently seen in tetralogy of Fallot than in isolated pulmonic stenosis. 21 Rich 23 in 1948 had recognized the increased tendency toward pulmonary arterial and venous thrombosis in tetralogy of Fallot and had ascribed these changes to the influence of polycythemia and sluggish flow. This concept was later supported by Heath et a1. 24 In commemoration, recanalized In cases of pulmonic atresia with tetralogy of Fallot, the lungs are sustained by systemic blood flow. The systemic collateral supply to the lung (not including the ductus arteriosus) may be one of three types: Type I, seen in most instances of tetralogy of Fallot, consists of hypertrophied bronchial arteries that anastomose with intrapulmonary arteries. Type II anastomoses, most common in pulmonary atresia, represent aortic vessels that anastomose to the junction of interlobar and intralobar pulmonary arteries near the hilum. Type III anastomoses originate from aortic branch vessels to supply the central pulmonary artery.8.20.25 Pulmonary hypertensive changes infrequently occur in uncorrected tetralogy as a result of direct systemic arterial supply. The repair of tetralogy of Fallot involves surgical construction of a systemic-pUlmonary shunt. In cases of large shunts, pulmonary hypertensive changes, including plexiform lesions and necrotizing arteritis, may result from the systemic flow. Complete correction of tetralogy of Fallot rarely results in postsurgical pulmonary hypertension. 20 . 26

In contrast to tetralogy of Fallot or pulmonic stenosis, in which medial thinning is diffuse, Wagenvoort2 7 has S.D. Groshong et al. reported on two patients, one a 20-year-old woman with pulmonary hypertension, and the other an ll-year-old girl with pulmonary arteriovenous fistulas and preportal hypertension, in whom muscular pulmonary arteries exhibited focal thinning or focal absence of the media immediately adjacent to medial hypertrophy ( Fig. 28.6 ). Marked intimal fibrosis was present overlying the thickened portion of the media but not over the defective media. The veins also exhibited arterialization immediately adjacent to zones in which muscle was deficient. Medial defects can be easily misdiagnosed as embolic pulmonary hypertension or veno-occlusive disease in lung biopsies. It is uncertain if medial defects predispose to arteriovenous aneurysms.

Misalignment of lung vessels is a fatal anomaly and a cause of persistent pulmonary hypertension of the newborn, in which dilated, thin-walled veins are juxtaposed to thickened muscular arteries in the peribronchiolar connective tissue (see Fig. 6 .32 in Chapter 6).28 From the earliest descriptions, misalignment of lung vessels has been associated with alveolar underdevelopment and interstitial fibrosis. 28 This constellation of histologic features is also known as alveolar capillary dysplasia and is further discussed in Chapter 6 on pediatric congenital malformations. 29 - 33 Pulmonary Hypertensive Vascular Disease Pulmonary vascular disorders encompass a wide range of clinical and pathologic entities affecting every compartment of the pulmonary vasculature. Lesions of the pulmonary arteries, arterioles, capillaries, and veins, while histologically distinct, may all result in an elevation of pulmonary pressure, and present with similar symptoms such as dyspnea with exertion, fatigue, syncope, and lower extremity edema. While many cases of pulmonary vascular disease are diagnosed by clinical setting, radiologic findings, and hemodynamic measurements, lung biopsy is undertaken in patients for whom the diagnosis remains elusive. 1 The evaluation of lung biopsies for vascular disease requires careful consideration of subtle, and often overlooked, changes within the pulmonary vasculature.

In hypertensive pulmonary vascular disease, intimal and medial hypertrophy can often be estimated by eye. However, analytic methods such as morphometry are valuable in comparative studies. There are several approaches to morphometry; a simple yet reliable approach proposed by Reid and colleagues 34 is to measure the thickness of the media and to express this as a percentage of the external vascular diameter. The intimal thickness is measured as a percentage of the internal vascular diameter, since this gives an indication of the degree of luminal obstruction. To minimize errors in sampling, 25 to 50 arteries are randomly selected for measurement. To accurately measure a vessel, cross sections should be circular or nearly circular.

With a calibrated eyepiece, measurements are made along a horizontal line traversing the diameter if the vascular cross section is circular, or along the shortest axis if the cross section is oval. Media (M1 and M2) and intima (11 and 12) traversed by this line on either side of the vessel are respectively measured using the elastic laminae as a boundary (Fig. 28.7) . The sum of the two measured values is divided by the external (ED) or internal (ID) vascular diameter to calculate the percentage medial (%MT) or intimal (%IT) thickness respectively: Normal values for %MT range from 3% to 7%; a thickness greater than 7% is considered to represent medial hypertrophy?5 1037 ED FIGURE 28.7. Vessel wall dimensions for quantitative assessment of medial and intimal thickness. MI, M2, medial thickness; 11 , 12, intimal thickness; ED, external vessel diameter; ID, internal vessel diameter.

Historical Approaches to Pulmonary Hypertensive Disease: Plexogenic Arteriopathy and Congenital Heart Disease The earliest classification system of pulmonary hypertension, the Heath and Edwards schema (Table 28.1) , was based on studies of patients with congenital heart disease. 4 In this system, disease severity was graded by histologic assessment alone. Since the schema is still widely used, it will be reviewed here. However, it is important to note that this approach only applies to pulmonary hypertension in the context of congenital heart disease, and attempts to extrapolate this grading system to other settings of pulmonary hypertension prove to be problematic.

Medial hypertrophy is the earliest and most widespread lesion that develops. The thickening of the media is attributed both to an increased number of smooth muscle cells, and to an increase in the size of those cells. 36 The normally nonmuscularized small arterioles (15 to 150jlm in diameter) also develop a layer of smooth muscle in a process referred to as muscularization of arterioles. The intima also undergoes a cellular proliferation of myofibroblasts and smooth muscle cells, with little or no deposition of elastin or collagen. Later the cellular intimal proliferation deposits collagen and elastin to form an onion-skin concentric laminar intimal fibrosis with a strong tendency to obliterate the central lumen. Dilation of arterial segments, thought to be the result of muscular incompetence and rising luminal pressure, results in large angiomatoidl dilatation lesions.

In advanced disease, fibrinoid necrosis may be seen particularly following bifurcation points in the arterial tree. A small segment of arterial wall becomes swollen with fibrin, followed by destruction of the smooth muscle layer and elastic laminae. Thrombus often forms within the lumen of the vessel. In addition, frank vasculitis with inflammatory exudates in the vessel wall and surrounding lung parenchyma may be seen.

A late-stage alteration in the sequence of changes is the development of the plexiform lesion itself. Like fibrinoid necrosis, these lesions typically develop distal to the bifurcation point of small pulmonary arteries. The artery is dilated and the lumen filled by a plexus of capillarysized vascular channels that are separated by cells with hyperchromatic nuclei.

The term plexogenic arteriopathy was proposed at a WHO meeting in 1975 to describe this characteristic morphologic pattern of hypertensive vascular changes in the lung. 37 This common morphologic progression is seen in relation to a number of etiologies including congenital heart disease with a left-to-right shunt, such as atrial and ventricular septal defects, patent ductus arteriosus, and persistent truncus arteriosus 38 ,39 (Table 28. 2). In addition, patients with tetralogy of Fallot may develop plexogenic arteriopathy as the result of large surgical shunts between the systemic and pulmonary circulation. 4 0-42 In addition to cardiac abnormalities, whether congenital or surgical, plexogenic arteriopathy is encountered most frequently in portal hypertension, collagen vascular diseases, drug use, familial disease, and idiopathic disease. Historically, the idiopathic and familial cases of the disease have been called primary pulmonary hypertension, while those cases attributable to another disease have been called secondary pulmonary hypertension. S.D. Groshong et al.

As described at the 1975 WHO meeting, the plexiform lesion is not a defining characteristic, but rather is a late step in a sequence of progressively more severe vascular changes. 37 It is therefore possible to have a biopsy that, while representing a disease process that falls under the auspice of plexogenic arteriopathy, does not contain the requisite plexiform lesion. Thus, finding even a single plexiform lesion imparts tremendous diagnostic significance. However, the term plexogenic arteriopathy was questioned by many pulmonary hypertension experts, as "plexogenic" implies a cause and effect, which may not necessarily exist. It was therefore deemed necessary to reclassify pulmonary hypertension in a way that provides meaningful clinical and prognostic data without placing excessive importance on the finding of a single histologic entity.

The WHO in 1998 adopted a revised classification for pulmonary hypertension that combines our understanding of clinical history, epidemiology, and pathology in an attempt to create a system that provides meaningful diagnostic and prognostic information across a wide range of disease entities. 43 In this classification scheme, the term secondary pulmonary hypertension was dropped in favor of pulmonary arterial hypertension related to [related condition).

In 2003, the nomenclature and classification were once again revised at the Third World Conference on Pulmo- (Table 28 .3). The revision was undertaken not only to address shortcomings in the WHO classification, but also to reflect the rapid advances that have been made in elucidating the pathogenesis of some pulmonary hypertensive states. The most recent recommendation is that the term primary pulmonary hypertension (PPH) be replaced with idiopathic pulmonary arterial hypertension (IPAH). Undoubtedly, as additional advances are made in understanding the pathogenesis and etiologies of the various forms of pulmonary hypertension, the nomenclature will undergo further changes. Both terms will be used here, as much of the literature is replete with the term primary pulmonary hypertension. Because vascular lesions can be overlooked in histologic sections, the WHO pathology working group also recommended a systematic approach to the evaluation of blood vessels as well as the surrounding lung tissue. This recommended approach is outlined in 

Pulmonary arterial hypertension is defined clinically as a mean resting pulmonary artery pressure greater than 25 mm Hg, or a systolic pulmonary artery pressure greater than 30mmHg.45 Mild elevations in pulmonary artery pressure are usually asymptomatic, and most cases are only diagnosed as the pulmonary artery pressure exceeds 60mmHg. Symptoms of pulmonary hypertension are related to right ventricular failure, or cor pulmonale, and include dyspnea, fatigue, syncope, lower extremity edema, and atypical chest pain. Clinical findings in cor pulmonale include right ventricular hypertrophy, manifested as a left parasternal or subxiphoid heave, split second heart sound, distended neck veins, peripheral edema, and pulsatile liver. Pleural effusions and ascites are uncommon. While death secondary to slowly progressive cor pulmonale is common in patients with severe pulmonary hypertension, some patients experience sudden death. Mechanisms of sudden death in these patients include arrhythmias, pulmonary hemorrhage, pulmonary embolism, and right ventricular ischemia. 46 The definition of cor pulmonale is problematic and varies within the medical literature from simple pulmonary hypertension to florid right heart failure due to underlying lung disease. 47 The morphologic definition of cor pulmonale espoused by the WHO expert committee is that of "hypertrophy of the right ventricle resulting from diseases affecting the function and/or structure of the lungs, except when these pulmonary alterations are the result of diseases that primarily affect the left side of the heart, as in congenital heart disease.,,47,48 As reviewed in Chapter 1, the morphologic standard for determining right ventricular hypertrophy is to separately measure and compare ventricular weights. 49

Sporadic cases are inclusively one of the forms of pulmonary hypertension formerly known as primary pulmonary hypertension. By definition, these are cases that are idiopathic despite extensive clinical evaluation for known associated diseases and exposures. The overall incidence of the sporadic form of the disease is not known, but is estimated to be 1 to 2 per million. While more common in young females (mean age, 36.4 years; male-to-female ratio, 1.0:1.7), sporadic pulmonary hypertension can occur at any age. 50 The disease can be seen in children and infants, and appears to have a similar sex ratio to that in adult patients, although the overall median survival appears to be lower in children. 51 There is an increased incidence of pulmonary arterial hypertension in children with Down syndrome that may be attributable both to the associated cardiac defects and the decreased number S.D. Groshong et al. and size of pulmonary arteries in those affected by Down syndrome. [52] [53] [54] The current model for pulmonary hypertension is based on endothelial damage, followed by inappropriate cellular proliferation. 45 Endothelial damage can occur through a variety of mechanisms, and may explain the diverse associations of pulmonary hypertension with viral infections, autoimmune diseases, and drug exposure. Human herpes virus-8 (the causative agent in Kaposi sarcoma) has been reported to occur in the lungs of at least 62 % of patients with primary pulmonary hypertension. 55 The virus leads to endothelial injury via the lytic phase of viral replication. In addition, p16 protein, which is associated with human papilloma virus infection and subsequent dysplasia,56 is expressed in plexiform lesions.

Inflammation triggering endothelial cell apoptosis, as described in scleroderma, may explain the association of collagen vascular disease with the development of pulmonary hypertension. 57 Irrespective of the mechanism of initial vascular damage, there is a complex reparative response involving the liberation of growth factors, alterations in receptor expression, and changes to the basic growth-regulatory machinery of cells. Serotonin and endothelin contribute to smooth muscle hyperplasia within pulmonary arteries. 58 ,59 Altered expression of hypoxia inducible factor-1 (HIF-1), vascular endothelial growth factor (VEGF) receptor II, and endothelin receptors have all been reported within the plexiform lesions of pulmonary hypertension. 60 Microarray studies of gene expression in lung tissue from patients with PPH demonstrate the loss of expression of tumor suppressor caveolin-1 and peroxisome proliferation-activated receptor-y (PPAR_y).61,62 It is postulated that the dysregulation of cell growth leads to an oligoclonal evolution of endothelial cells, in a process that closely parallels neoplasia. 63

Familial pulmonary arterial hypertension (FPAH) is rare and accounts for less than 6% of all primary pulmonary hypertension patients. The disease presents at an earlier age as compared with spontaneous cases, and appears to have an autosomal dominant inheritance pattern with incomplete penetrance. 64 Only 10% to 20% of family members develop the disease. Despite the autosomal dominant inheritance, the disease shows a female predominance, similar to the spontaneous form of the disease.

The familial form of pulmonary arterial hypertension has provided a rare opportunity to investigate the genetic basis of pulmonary hypertension predisposition. Germline mutations in bone morphogenetic protein receptor-II (BMPR2 [chromosome 2q31-32]), a gene that encodes a receptor in the transforming growth factor-~ (TGF-~) superfamily, have been identified in patients with FPAH. 65 Interestingly, 26% of a series of 50 patients with IPAH were also found to carry the BMPR2 mutation. 66 It is clear, however, that genetic susceptibility does not explain all cases of severe IPAH.

All forms of collagen vascular disease have been seen in association with pulmonary hypertension. 67 However, there is a wide range of risk based on the clinical classification of collagen vascular disease. CREST syndrome (calcinosis, Raynaud's phenomenon, esophageal dysfunction, sclerodactyly, and telangiectasia), a variant form of systemic sclerosis, has a very high incidence of pulmonary hypertension with up to 10% to 30% of patients affected, and over 50% with evidence of pulmonary hypertension at autopsy.68 A similar incidence has been reported in patients with mixed connective tissue disease. 59 Systemic lupus erythematosus has a somewhat lower risk, with approximately 5% to 10% of individuals affected. 70 Sjogren's disease, rheumatoid arthritis, and polymyositis/ dermatomyositis rarely develop associated pulmonary hypertension. 7 ! The pathogenesis of pulmonary hypertension in the setting of collagen vascular disease is not well established. Inflammation is believed to play a pivotal role in the development of pulmonary hypertension. Clustering of T cells and macrophages around vessels has been reported and may be linked to vascular remodeling. 72 The liberation of cytokines such as VEGF and platelet-derived growth factor (PDGF) in an inflammatory response may drive endothelial proliferation in these patients. 73 ,74 In patients with collagen vascular disease-associated hypercoagulable states, such as lupus anticoagulant or antiphospholipid antibodies, in situ thrombosis may play a role in the development of arteriopathy and pulmonary hypertension (see Chapter 20) . 75, 76 Portal Hypertension Portal hypertension, most commonly in the setting of liver disease, can be associated with pulmonary hypertension. Typically, pulmonary hypertension develops 4 to 7 years after the initial diagnosis of portal hypertension. 77 Portopulmonary hypertension (PPHTN) is seen in 0.25% to 0.73% of patients with liver cirrhosis irrespective of the cause of cirrhosis. A higher percentage (2 %) was reported in a cardiac catheterization-based study.78,79 Furthermore, the risk of pulmonary hypertension is associated with the duration of portal hypertension, but does not correlate well with the degree of portal hypertension.

It is believed that circulating factors and cytokines are responsible for the development of pulmonary hypertension in this setting. Endothelin -1 (ET-l), a vasoconstrictor 1041 and endothelial mitogen, has increased synthesis and reduced metabolism in cirrhotic patients, resulting in increased plasma concentrations. 80 ,8) Human Immunodeficiency Virus Human immunodeficiency virus (HIV) appears to be a potent risk factor for the development of pulmonary hypertension, with an incidence of approximately 0.5% in the HIV-positive population-at least a 2000-fold increase in risk as compared with the general population. 82 Unlike many of the complications of HIV, pulmonary hypertension appears to correlate poorly with CD4 counts or stage of infection. The mean CD4 count for those with HIV and pulmonary hypertension is 300/mm 3 , with a range of 0 to 900/mm3, and less than one third of these patients meet the clinical definition of AIDS. 83 . 84 The development of pulmonary hypertension in HIVpositive patients with no other risk factors initially led researchers to suspect a direct mechanism via viral infection of endothelial cells. However, HIV viral sequences have not been recovered from endothelial cells of affected patients, nor have viral particles been identified by electron microscopy.85 Therefore, the current models of HIVassociated pulmonary hypertension have focused on the role of cytokines in the mediation of HIV's effect. Platelet-derived growth factor may, at least in part, mediate some of the endothelial proliferation in response to HIV infection.s6 In addition, ET-l, a potent vasoconstrictor and mitogen produced by macrophages, appears to be increased by the HIV gp120 protein. 87 Furthermore, there does appear to be correlation between ET-l immuno staining and the overall pulmonary vascular resistance. 88 While virally mediated cytokines may facilitate the development of pulmonary hypertension, the majority of HIV-positive patients do not have elevated pressures. This would suggest, therefore, that there are other host factors involved in the development of disease. Of particular interest is the association of HIV-associated pulmonary hypertension with specific human leukocyte antigen (HLA) DR alleles. 89 Drugs

The diet drug combination of fenfluramine (Pondimin) or dexfenfluramine (Redux) in combination with phentermine (commonly referred to as Fen-Phen) was a popular diet regimen in the 1990s, with over 18 million prescriptions written by 1996. On September 15, 1997, American Home Products (AHP) Corporation, now known as Wyeth, withdrew the drugs Pondimin and Redux from the marketplace after the New England Journal of Medicine published a report of 24 patients who had developed valvular heart disease. 9o The Food and Drug Administration (FDA) acted rapidly, issuing a warning on September 17, 1997, that cardiovascular symptoms could be seen in up to 30% of patients taken Fen-Phen. In addition to valvular heart disease, the drugs had been previously also linked to a 28-fold increase in incidence of pulmonary hypertension, resulting in a purported incidence of 28 per million, as opposed to 1 per million for the general population. 91 However, in absolute numbers, the number of patients developing pulmonary hypertension was dwarfed by the number who reported heart valve disease.

The legal response to the newly found associations was brisk, resulting in thousands of lawsuits and class actions, finally culminating in a settlement on September 1,2000, establishing the AHP Settlement Trust, which accepted new claims for benefits up to the date of August 1, 2002 (also referred to as Date 1). By January 31,2005, Wyeth had estimated the litigation costs to be $21.1 billion, making it one of the most expensive settlements in history.

Histopathologically, plexiform lesions have been described as the main vascular alteration in fenfiuraminephentermine-associated pulmonary hypertension,92,93 although the case reported by Strothers et a1. 94 was suggestive of thrombotic arteriopathy. It has been postulated that the serotonergic activity of these drugs, in combination with an underlying polymorphism in the gene encoding a serotonin transporter, is responsible for the development of pulmonary hypertension in patients taking Fen-Phen (see Aminorex Aminorex fumarate was a powerful appetite suppressant popular in the late 1960s in West Germany, Austria, and Switzerland, although it was never approved for use in the United States. 97 The drug was responsible for an epidemic of pulmonary hypertension, beginning in 1967 and ending by 1972. Half of the affected patients were alive in a 10-year follow up, with most dying of right-sided heart failure. 91 ,98 In a later analysis, it appears that aminorex is more highly correlated with the development of pulmonary hypertension than is dexfenfiuramine, and was responsible for a fivefold increase in the number of pulmonary hypertension cases, as compared with the number expected for the same time period. 99 Toxic Oil Syndrome Toxic oil syndrome was described in Spain in 1981 following the illegal sale of rapeseed oil containing aniline. The syndrome involved liver disease, motor neuropathy, eosinophilia, pulmonary infections, and pulmonary hypertension. It is estimated that 20,000 people were affected, and over 2500 deaths have been attributed to the S.D. Groshong et a1. ingestion of toxic rapeseed oi1. lOO Pulmonary hypertension was seen in up to 20% of patients following ingestion, although many cases appeared to spontaneously resolve. 101 However, some cases progressed, and were clinically and pathologically analogous to the idiopathic form of the disease, with right ventricular failure seen as early as 2 months following ingestion of the tainted oil. 102 Although the mechanism of the development of pulmonary hypertension in these patients is not known, it is suspected to involve direct endothelial toxicity by aniline. 101 Amphetamines, Methamphetamines, and Cocaine Stimulants such as amphetamine, methamphetamine, and cocaine have been associated with the development of pulmonary hypertension. 103 .104 While these drugs do have structural similarity to fenfiuramine and aminorex, it has been proposed that it is contaminants in the preparation of these substances, rather than the drug itself, that causes pulmonary hypertension. 104 Studies of patients with pulmonary hypertension associated with use of these drugs have often found foreign-body granulomas and microembolization in pulmonary arteries. 105 Drug additives believed to play a role, whether inhaled, smoked, or injected, include talc, corn starch, ascorbic acid, boric acid, plaster of Paris, phencyclidine, heroin, lidocaine, and phenytoin. I06 .107 It remains unclear whether the stimulants themselves play a role in the development of pulmonary hypertension, although it has been proposed.lO s

The dietary supplement L-tryptophan has been associated with an eosinophilia-myalgia syndrome that includes pulmonary manifestations including pulmonary hypertension. 109 Finding at lung biopsy in these patients have included vasculitis, perivasculitis, follicular bronchiolitis, chronic interstitial pneumonia, pulmonary eosinophilia, and fibrointimal hyperplasia of pulmonary vasculature.llO.l ll High-dose steroids provided only partial resolution of the pulmonary symptoms in one small series. 111 Phenylpropanolamine Phenylpropanolamine was commonly found in overthe-counter antiobesity medications as well as some cold remedies until its removal from the market in 2000 due to increased risks of hemorrhagic stroke. 112 The Study of Pulmonary Hypertension in America (SOPHIA) incidentally discovered an association between phenylpropanolamine and the development of pulmonary 

The pulmonary trunk and main pulmonary arteries in the fetus and newborn resemble the aorta in diameter, mural thickness, and elastic configuration ( Fig. 28.8 ). Long continuous elastic fibers are circumferentially arranged in a parallel fashion within the pulmonary arterial wall.1l4-116 After birth, as the pulmonary circuit assumes a lower pressure and resistance, the central elastic pulmonary arteries acquire a wall thickness less than that of the aorta with a postnatal "adult" configuration of interrupted, irregular elastic fibers ( Fig. 28.8) . 115 Lobar and more distal arteries, however, retain a circumferential elastic pattern. In patients with low-flow states, such as tetralogy of Fallot, the pulmonary artery may be further thinned and the interrupted pattern of elastic fibers accentuated. 114 However, when pulmonary hypertension persists from birth, as in certain congenital heart defects with left to right shunt, the normal transformation of elastic pattern in the central pulmonary arteries does not occur, and the arteries retain a fetal or "aortic" configuration of dense continuous mural elastic fibers (Fig. 28 .8D).l15 

Macroscopically, when severe pulmonary hypertension is present, parenchymal pulmonary arteries are rigid and stand above the surrounding parenchyma. While many cases of pulmonary arterial hypertension are diagnosed clinically without lung biopsy, histopathologic evaluation can playa critical role in the diagnosis of patients with atypical clinical presentations. A common change in pulmonary arterial hypertension is medial hypertrophy of arterial walls (Fig. 28.12 ). In children, muscularization of arterioles may be the only histologic finding in pulmonary hypertension. While this appears to be rarely the case in adults, it has been described in chronic hypoxia. 121 Normal medial thickness in adults is 3% to 7% of the external vascular diameter. Mild hypertrophy ranges from 7% to 9%, moderate hypertrophy has a thickness of 10% to 14%, and severe disease typically has a thickness in excess of 15 % . 122 There is often good correlation with the thickness of the medial smooth muscle and the measured pulmonary artery pressure. In contrast, intimal hyperplasia, while a common finding in pulmonary hypertension, has poor correlation with the severity of disease. Intimal hyperplasia is seen in two distinctive forms. Cellular intimal hyperplasia, a relatively nonspecific finding, is loose and lacking in collagen deposition ( Fig. 28.13 ). Concentric laminar intimal hyperplasia, on the other hand, has dense deposition of collagen and elastin, and is a finding rarely seen except in primary pulmonary hypertension or other conditions, as described above, in which plexiform lesions develop ( Fig. 28 .14). Concentric intimal fibrosis is often present upstream to a plexiform lesion, as shown by three-dimensional vascular reconstruction ( Fig. 28.15 ).123 Occasionally, dilation creates vessels with large lumina and very thin walls that are reminiscent of pulmonary veins, so-called dilatation lesions ( Fig. 28.16 ).

Plexiform lesions are the hallmark angioproliferative lesion of severe primary pulmonary hypertension, and FIGURE 28.14. Concentric laminar intimal hyperplasia. A. This example of intimal hyperplasia demonstrates a concentric laminar, onion-skin appearance. There is associated marked narrowing of the lumen. B. The Movat stain highlights the FIGURE 28.15. Three-dimensional reconstruction of a pulmonary artery and its branches in a case of primary pulmonary hypertension (PPH). This computerized three-dimensional reconstruction of the endothelial cell layers (blue) in a mediumsized pulmonary artery of a patient with PPH demonstrates that the plexiform lesions occur in the branching vessels, distal to the parent artery. Points of constriction, corresponding to concentric intimal lesions, are present just proximal to the plexiform lesions. The red highlights the luminal spaces of the vessels.

are characterized by an abnormal proliferation of endothelial cells forming multiple irregular lumina in a glomeruloid plexus (Fig. 28.17 ). Unlike the rigid round lumina of a recanalized thrombus, the plexiform lesion predominantly intimal nature of this lesion. The smooth muscle layer between the two elastic laminae is only mildly hypertrophied. tends to form asymmetrical and slit-like channels within the vessel (Fig. 28.18 ). Plexiform lesions may be very sparse in a case, requiring examination of multiple sections, or may be widespread. While plexiform lesions are characteristic of the idiopathic and familial forms of pulmonary hypertension, they are not pathognomonic and may be seen in any case of severe pulmonary arterial hypertension.

Although rarely seen in treated patients, fibrinoid necrosis has been described in small vessels less than 100f-lm in diameter, showing fibrin and necrosis within the medial smooth muscle. Fibrinoid arteritis has also been described as a feature of larger arteries, with acute inflammation throughout the vessel wall and adventitia ( Fig. 28.19 ). Both fibrinoid necrosis and arteritis are features of severe pulmonary arterial hypertension, and usually suggest a more aggressive clinical course. Thromboembolic lesions are now rarely seen in patients with severe idiopathic pulmonary arterial hypertension because these patients are usually effectively treated with anticoagulants.

In cases of pulmonary arterial hypertension associated with collagen vascular disease, the vascular adventitia may be markedly thickened with collagen ( Fig.  28.20 ). In addition, these cases may show other features of collagen vascular disease, such as constnctIve bronchiolitis and lymphoid aggregates with germinal centers. FIGURE 28.19 . Fibrinoid arteritis. There is extensive fibrinoid necrosis and perivascular inflammation in this muscular artery from a patient with ventricular septal defect and pulmonary hypertension.

Since the symptoms of early primary pulmonary arterial hypertension are subtle and nonspecific, the disease is typically diagnosed late in its course. The natural history is one of relentless progression to right -sided heart failure, FIGURE 28 .20. Adventitial fibrosis. Often the clue to a collagen vascular disease etiology for pulmonary vascular disease can be found in the markedly thickened, collagenized adventitia. with a median survival of 2.8 years between diagnosis and death, in untreated patients. 124 Current treatment regimens have improved the survival considerably. Oxygen is used to treat patients with dyspnea and prevent further vasoconstriction from hypoxia. Patients have also been shown to derive benefit from long-term anticoagulation with warfarin. 125 While oral vasodilators, such as calcium channel blockers, can provide long-term benefit, only 20% of patients with primary pulmonary hypertension respond to calcium channel blockers. 126 Perhaps the most important advance in the treatment of IPAH has been the use of the prostacyclins, such as epoprostenol. Prostacyclins are potent, short-acting vasodilators and inhibitors of platelet aggregation that have improved exercise tolerance, quality of life, and longterm survival in patients with severe pulmonary arterial hypertension. 127 Unfortunately, the 6-minute half-life of the drug necessitates a complex delivery system capable of continuous intravenous administration. Cessation of the drug, even for a short time, can result in fatal rebound pulmonary hypertension. Despite the advancement in the medical management of primary pulmonary hypertension, many patients ultimately require lung transplantation. Lung transplant recipients with primary pulmonary hypertension have a reported I-year survival of 73%, and a 5-year survival of 45%.128 To our knowledge, there have been no reports of recurrent primary pulmonary hypertension following lung transplantation.

Associated forms of pulmonary arterial hypertension have typically utilized very similar treatment modalities, while also attempting to treat the underlying condition. Collagen vascular disease-associated pulmonary arterial hypertension has often been treated with immunosuppression in addition to the modalities used in primary pulmonary hypertension. While there have been reports of improvement following immunosuppression, there are no controlled studies that have demonstrated a benefit in long-term survival. 129 Similarly, antiretroviral therapy in HIV has had mixed results, with reports of regression of pulmonary hypertension, as well as other reports of accelerated disease during treatment. 130 . l3l

Pulmonary artery aneurysm (PAA) is an exceedingly rare lesion. A comprehensive autopsy study by Deterling and Clagett 132 documented only eight cases out of 109,571 «0.01 %) autopsies. The classification and etiologies of pulmonary artery aneurysm are summarized in Table 28 .5.133 A basic division of PAA lies between aneurysms with and those without arteriovenous communication.133 S.D. Groshong et al. Etiology Infection (mycotic aneurysm) is an important cause of proximal PAA and some cases of arteriovenous aneurysms. 133 -135 Historically syphilis and tuberculosis were the most frequent infectious causes, but the pathogenesis differs greatly between the two entities. Syphilitic aneurysms are the result of chronic inflammation of the vasa vas ora of proximal pulmonary arteries, while tuberculous (Rasmussen) aneurysms are the effect of inflammation and necrosis of more distal arteries traversing, or adjacent to, cavitary lesions in chronic progressive tuberculosis. A variety of other bacteria or fungi, notably Staphylococcus aureus and streptococci, may give rise to mycotic aneurysms.133.1 34 Infectious agents also interact with congenital or acquired risk factors to contribute to the development of aneurysms. 13 4-137 Intravenous drug users who develop right-sided valvular endocarditis are a selective population at risk for mycotic PAA. 138 Other predisposing factors contributing to nonarteriovenous PAA include congenital heart disease, pulmonary hypertension, and vasculitis. 139. 140 Congenital cardiac anomalies accounted for 56% of central PAA in two autopsy series.132,l41 The two most frequent anomalies are patent ductus arteriosus and atrial septal defect.l33. 142.143 The mechanism of aneurysm formation may act through myxoid degeneration of the elastic arterial wall. D3. 144.145 This degenerative condition has been well described in aortic aneurysm and is frequently seen in elastic pulmonary arteries in patients with pulmonary hypertension (Fig. 28.9 ) (see above). Marfan syndrome, a systemic congenital disorder of connective tissue, is associated with medial myxoid degeneration, not only of the aorta, but also of pulmonary arteries, and occasionally is associated with PAA. 133 The presence of fever and hemoptysis in these patients has suggested an infectious etiology, which has never been proven. 133 It has also been theorized that Hughes-Stovin syndrome is a variant of Behc;et disease. 152 ,153 Trauma is another important cause of acquired PAA. Traumatic injury may be extrinsic due to blunt impact or penetrating lacerations, or intrinsic due to endovascular injury.1s3 The latter is usually an iatrogenic complication of pulmonary artery catheters or embolotherapy using devices such as metal coils or balloons to control hemoptysis. m ,154 Intravascular coils have the potential to migrate through the vessel wall causing structural weakening and predisposing to aneurysm development (see Fig. 40 .24 in Chapter 40). Arteriovenous communicating aneurysms are mostly congenital in nature and may be isolated (60% of cases) or associated with hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease) in 40% of casesY3 Arteriovenous aneurysms are usually peripheral and present as one or more nodular densities on chest imaging studies.

Pulmonary artery aneurysms are notoriously difficult to diagnose clinically due to the nonspecificity of signs and symptoms. Typical manifestations are cough, dyspnea, chest pain, and hemoptysis, the latter being a frequent initial manifestation. 133 Central aneurysms cause a prominence of the pulmonary artery on chest x-ray, which can be confused with other causes of radiographic hilar or mediastinal enhancement. Sudden death due to rupture is an important complication of PAA. In some cases an intimal tear with or without mural dissection may precede rupture. 136,137,144 Central aneurysms may be replaced surgically with a prosthetic graft. The standard treatment of peripheral arteriovenous aneurysms is embolotherapy.154

The histopathology of PAA depends on the underlying cause and the location of the vessel (central vs. peripheral). In the series of cases studied by Butto and colleagues136 in five patients with pulmonary hypertension, pulmonary arterial dilatation and saccular aneurysms were associated with intimal tears, fibrotic neointimal lesions, or laminar thrombi (three patients each); mural dissection (two patients); and ulcerated atheromas or calcification (one patient each) ( Fig. 28.21) .

B. Marked degeneration of mural elastica (arrow) adjacent to and infiltrated by organizing hematoma. L = lumen thrombus. (Movat stain.) Medial myxoid degeneration was described as prominent in four of five patients. For peripheral arteriovenous aneurysms, a network of dilated vessels with a variable amount of smooth muscle, elastic fibers, and collagen is seen histologically (see Fig. 40 .22 in Chapter 40).

Epidemiology Pulmonary thromboembolism (PTE) is a frequent clinical event, a major cause of respiratory symptoms, and an important cause of death, including sudden unexpected death (see Chapter 31).155-157 Precise statistics on the incidence of PTE are difficult to determine, and vary with the mode of study (i.e., clinical versus autopsy evaluation). It has been estimated that 600,000 persons each year in the United States experience PTE, resulting in approximately 300,000 hospital admissions and 50,000 deaths (10%). This likely represents a conservative estimate since the clinical diagnosis of PTE is notoriously difficult due to the nonspecificity of associated cardiorespiratory symptoms or the absence of symptoms in many cases. Furthermore, the lack of autopsy confirmation in the majority of fatal cases is a major impediment in determining the true incidence of fatal PTE. ISS Even autopsy studies, however, do not provide a clear picture of the incidence of PTE, which is highly dependent on the thoroughness with which emboli are sought postmortem, and ranges widely from 6% to 69%.155,159-161 A reasonable incidence of PTE documented at autopsy is 40% to 50%.162 Pulmonary thromboembolism is estimated to be the solitary or major contributory cause of death in 3.5% to 18.1 % of adults in acute general hospitals. 155,1 59-161.163

Although primary thrombosis of the pulmonary artery may occur (see below), the majority (90%) of pulmonary emboli originate as thrombi in the deep leg veins. 156 ,164 Therefore, patients most at risk for PTE are those also at risk for the development of deep venous thrombosis, notably patients with underlying heart disease, malignancy, or shock. Other important predisposing factors include hypercoagulable states, obesity, oral contraceptives, pregnancy, and postoperative status, especially following orthopedic surgery.lS7 Most thrombi which give rise to PTE reside in the iliofemoral veins, as opposed to the superficial leg veins. 156 ,164 Outside of the deep leg veins, other venous beds such as the periuterine or periprostatic plexus may give rise to emboli. Indwelling central catheters, including Swan-Ganz catheters, are a cause of thrombi in the superior vena cava, and a poten-S.D. Groshong et al. tial source of PTE. lo5 Atrial fibrillation may occasionally dislodge thrombi in the right atrial appendage. Disorders that predispose to clotting such as antithrombin III deficiency, factor V Leiden, deficiency of protein C, or the presence of lupus anticoagulant (antiphospholipid syndrome; see Chapter 20) may also predispose to venous thrombosis and PTE in approximately 10% to 15% of patients (see Chapter 31 for discussion of inherited thrombophilia ).156

There are no typical or specific presenting signs and symptoms of PTE. Dyspnea, tachypnea, and chest pain are seen in the majority of patients. 159 ,166 Nonproductive cough occurs in about 50%, while hemoptysis, wheezing, fever, or pleural friction rub are variable signs or symptoms in less than 50% of patients. The chest x-ray is equally nonspecific and may be normal in up to 20% to 30% of patients, including those with massive pulmonary emboli. 155 ,156 Transient radiographic infiltrates are common, but persistent opacities due to infarction occur only in about 10% of patients. Other radiographic features include elevation of the hemidiaphragm, linear atelectasis, or pulmonary oligemia (Westermark's sign).15S,159 Electrocardiogram changes are abnormal, but often transient and nonspecific, in the majority of patients. Hypoxemia «80mmHg) occurs in about 85% of patients, and many also exhibit hypocarbia secondary to tachypnea and hyperventilation. Small unilateral, transient pleural effusions are seen in about one third of patients, but there are no diagnostic laboratory studies of pleural fluid that indicate a pulmonary embolus has occurred. Other tests used widely in the clinical evaluation of patients with suspected PTE are ventilation/perfusion lung scan, spiral computed tomography (CT) scan, Doppler imaging of leg veins, and serum analysis for D_dimer. 164 ,167,168 Pulmonary angiogram is still considered to be the clinical gold standard for diagnosing PTE, but this modality is being replaced by CT imaging, and is performed infrequently.ls7

Morphologically, an acute fatal pulmonary embolus often presents as one or more deep red, firm, coiled clots situated in the pulmonary trunk and extending into the main pulmonary arteries (saddle embolus) (Fig. 28.22A) . 169 When uncoiled, the embolus often is seen as a cast of the deep leg veins in which it was formed (Fig. 28.22B) . Less frequently smaller emboli in mUltiple lobar or segmental arteries may cause death. Typically, pulmonary emboli fill and distend the pulmonary artery, which may be surrounded by acute adventitial hemorrhage. On cross section, alternating dark red and lighter striations (lines of Zahn) represent sequential layering of erythrocytes and fibrin/platelets within the thromboembolus (see Fig.  31 .13 in Chapter 31). Upon close inspection, the imprint of the venous valves may sometimes indent the surface of the embolus. 169 ,170 Acute microscopic changes in the pulmonary artery following impaction of an embolus include dilatation and congestion of adventitial vessels, perivascular hemorrhage, and acute inflammation of the pulmonary arterial wall (Fig. 28.23 ).171 In patients with acute fatal pulmonary embolism, additional smaller orga- From the pathologist's perspective, it is important to distinguish antemortem emboli from postmortem clots (Table 28 .6). Compared to the macroscopic features of emboli reviewed above, postmortem clots tend to be soft, gelatinous, and biphasic (red/yellow) in appearance due to the passive settling of erythrocytes and aggregation of leukocytes ("chicken fat" clot). Postmortem clots form a loose, nondistensive cast of the branches of the pulmonary artery in which they arise (see also Chapter 31)Yo

Histologically an acute fatal embolus is marked by layering of erythrocytes and condensed fibrin (Fig. 28.24A) . A variable number of neutrophils may be entrapped within the clot. When sheets of neutrophils are present, a septic embolus should be considered (see below). One of 

In those situations that are not immediately fatal, acute emboli may be dissolved by thrombolytic action, allowing restoration of blood flow. If thrombolysis is incomplete, the process of organization begins within about 1 to 3 days. 172 The early phases of organization involve migration of fibroblasts, myofibroblasts, and primitive mesenchymal cells from the blood vessel subintimal layer into the clot (Fig. 28 migrate into and over the surface of the clot. In larger pulmonary arteries, hemosiderin-laden macrophages and primitive capillaries are part of an exuberant granulation tissue reaction that extends into the embolus (Fig. 28 .24C) and gradually converts it into a fibrous lesion that may be eccentric, or bridge the lumen as an intravascular web (see Fig. 28 The organization of intravascular thrombi or emboli has been divided into six overlapping histologic phases by Irniger172,174 (Table 28 .7; Fig. 28 .24). The timetable governing these phases of organization likely varies with the type and size of the involved vessel. In attempting to date the onset of a pulmonary thromboembolus, one must be cognizant that some degree of organization may have occurred at the systemic site of origin (see Chapter 31). Subsequent propagation of more recent thrombus may also occur within the pulmonary artery. In general, dating is considered to be approximate at best, and often unreliable. 172

By definition, pulmonary infarction implies ischemic necrosis of lung tissue. As demonstrated in the 1940s by Castieman,175 and confirmed in subsequent studies, pulmonary infarction is a relatively infrequent event following pulmonary embolism. In a large autopsy series, Havig 161 found lung infarcts in 20% of cases as opposed to pulmonary emboli in 69%. The rich collateral blood supply to the lung through bronchial arteries, the pulmonary capillary bed, and possibly via retrograde flow in the pulmonary veins sustains the viability of lung tissue distal to pulmonary arterial occlusion. 176 Infarction tends to occur with peripherally situated emboli, and in patients with underlying heart failure, lung cancer, or emboli to more than one 10be. m ,17s

The earliest stage in the development of lung infarction, sometimes called the stage of preinfarction or incipient infarction, is histologically represented by capillary congestion and acute alveolar hemorrhage and edema, without lung necrosis. 178 ,179 The source of alveolar hemorrhage is probably derived from bronchial arteries via precapillary anastomoses. 176 If adequate collateral circulation commences, edema and hemorrhage may clear, and lung viability and architecture are preserved, thus accounting for the transient nature of alveolar infiltrates seen radiographically. As necrosis develops, alveolar septal nuclei disappear and a variable degree of acute inflammation occurs. The gross appearance of a recent lung infarct is that of a pleural-based hemorrhagic zone of parenchymal induration, the proximal portion of which forms a convex hump directed toward the hilum (Fig. 28.27 ).179 An occluded vessel is often seen proximal, but not necessarily adjacent, to the infarct (Fig. 28.28A) .

Organization of an infarct proceeds centripetally from the periphery as granulation tissue and hemosiderinladen macrophages extend from adjacent viable parenchyma to replace necrotic lung (Fig. 28.28B) . Squamous metaplasia and endarteritis obliterans are frequent histologic findings in the region of an organizing infarct. Elastic stains are helpful in discerning the remnant elastic framework of lung parenchyma in the necrotic center of the infarct. Macroscopically organizing infarcts are yellow- from infective thrombophlebitis, indwelling vascular catheters, or right-sided valvular endocarditis. On chest x-ray or CT scan, septic emboli appear as multiple periphh . . 181182 R eral lung nodules t at progress to caVItatIOn.· are instances of cavitation of noninfected infarcts have also been reported.180.183 Infarcts resulting from peripheral emboli may have a more rounded or lobular contour and radiographically simulate a neoplasm, sometimes prompting surgical resection. 184 Organizing fibrinous pleuritis is usually seen in the visceral pleura overlying an infarct.

Completely organized infarcts take the form of peripheral subpleural scars often associated with overlying pleural fibrosis and adhesions. At times the scar may be slit-like, with a deep pleural retraction producing a pseudo-fissure ( Fig. 28.30 ). Elastic stains of organized lung infarcts show collapsed, entangled elastic fibers within a collagenous stroma (Fig. 28.31 ).175

Organized thromboemboli in the major or peripheral pulmonary arteries may be an occult cause of pulmonary hypertension and respiratory failure.185-189 Symptomatic chronic thromboembolic pulmonary hypertension affects approximately 3.8% of patients within 2 years following an episode of pulmonary embolism. 190 In some cases massive thrombotic occlusion and dilatation of the pulmonary artery suggests primary thrombosis as the underlying etiology, rather than organization of an embolus (Fig. 28.32) . 191, 192 However, unless an underlying defect of 1055 FIGURE 28.31. Histologic pattern of organized lung infarct includes entangled, thick elastic fibers in a collagenous background. (Elastic van Gieson.) the artery exists, it is more likely that even massive clots were initiated by emboli.I7O When significant central arterial occlusion occurs, the bronchial and intercostal collateral arteries greatly enlarge to supply the lung. Pulmonary artery endarterectomy may successfully remove fibrous tissue from within the central pulmonary artery, thereby restoring FIGURE 28.32. Massive thrombosis of central pulmonary artery (arrow) in patient with honeycomb lung. Pulmonary artery is greatly dilated. Layered thrombus resembles that seen in abdominal aortic aneurysms. circulation and alleviating symptoms (Fig. 28.33) . 186, [193] [194] [195] Patients with massive unilateral thrombotic occlusion of the pulmonary artery tend to do more poorly after thromboendarterectomy than patients with bilateral occlusion. 196 The development of postobstructive small vessel occlusive vasculopathy in the ipsilateral lung has been proposed by Hirsch and colleagues l96 to account for this tendency.

Upon review of a large series of endarterectomy specimens, Blauwet et al. 197 noted that thromboendarterectomy was usually bilateral, with a larger amount of tissue removed from the right pulmonary artery. Most patients did not have identifiable coagulation disorders or auto-S.D. Groshong et al. immune diseases. The histologic features of the extracted organized thromboemboli included collagen (100% of cases), elastin (67%), hemosiderin (56%), inflammation (53%) , atherosclerosis (32%) , and calcification (15% ) . 197 These authors encountered three cases in which primary pulmonary artery sarcomas presented clinically as chronic thromboembolic obstruction of the pulmonary arteries. Sclerosing mediastinitis with compression of central pulmonary arteries, and congenital unilateral absence of the pulmonary artery are two other important entities that may clinically simulate chronic thromboembolic occlusion of major pulmonary arteries. 16. 1 98.199 A study of the peripheral small pulmonary arteries of patients undergoing or following thromboendarterectomy for major vessel thromboembolic pulmonary hypertension disclosed a variety of lesions including concentric and eccentric intimal fibrosis, recanalized thrombi , and plexiform lesions. 20o Importantly, the presence of plexiform lesions was not pathognomonic for primary pulmonary hypertension nor did it exclude a diagnosis of chronic thromboembolic pulmonary hypertension. 2oa The organization of pulmonary emboli in small elastic and muscular pulmonary arteries recapitulates the pattern seen in the central arteries, that is, eccentric intimal fibrous lesions or recanalized "web lesions" (Fig. 28.34) . 170 In microembolic pulmonary hypertension, showers of emboli occlude the peripheral vascular bed resulting in the insidious onset of dyspnea, pulmonary hypertension, and cor pulmonale. 187 ,20 1 As Wagenvoort l69 ,170 astutely points out, the presence of a central thromboembolus associated with numerous distal microemboli is suggestive of fragmentation and dispersal of an upstream pulmonary embolus.

The typical morphology of organized thromboemboli enables the recognition and distinction from plexiform lesions (see Figs. 28.17 and 28.18). Some cases of unexplained pulmonary hypertension may have a mixture of thromboembolic and plexogenic features. These cases likely derive from primary thrombosis rather than microembolization.

The mainstay of prophylactic treatment for pulmonary embolism is anticoagulant therapy. In cases of failure of anticoagulant therapy or of multiple recurrent emboli, placement of an inferior vena caval filter device may be considered. Acute treatment of a recent embolus may include thrombolytic therapy or infrequently, embolectomy. Relatively few patients (approximately 2.5 %) with clinically diagnosed and properly treated pulmonary emboli die acutely of pulmonary embolism. 202 Death within 1 year of a documented embolic event is usually due to another underlying disease like heart failure, cancer, or chronic lung diseases. 202 Paraskos et aU03 also determined that the long-term survival of patients who survive acute embolism is dependent on the absence of prior heart disease.

In patients with symptomatic chronic thromboembolic occlusion of major pulmonary arteries, pulmonary thromboendarterectomy may be performed and ameliorate pulmonary hypertension. 186 Thrombi that originate distal to the proximal segmental arteries, however, are not amenable to endarterectomy. l86 Mortality rates for this procedure range from 5% to 24%. Reperfusion injury is a frequent complication (see Chapter 23) . Patients with persistent pulmonary hypertension due to small vessel microembolization may be candidates for lung transplant.

Pulmonary thromboembolism is important in the pathogenesis of lung injury in sickle cell disease (SCD). This autosomal recessive hereditary hemoglobinopathy is caused by a point mutation at the sixth position of the ~-globin chain in which valine is substituted for glutamic acid. 204 Approximately 8% of African Americans are heterozygous for the sickle mutation, while 0.15% are homozygous. 20S Pulmonary complications of SCD are a major cause of morbidity and are responsible for an estimated 21 % to 85% of deaths.20s Historically, lung involvement in SCD has been differentiated into (1) acute chest syndrome, and (2) chronic lung disease.2os. 206 Patients with SCD are also at increased risk for pneumonia, especially pneumococcal pneumonia, as a result of splenic infarction and autosplenectomy.207-2o9 Patients who are heterozygous for the sickle cell mutation (i.e., sickle cell trait) may also 1057 be at increased risk for pulmonary complications, but at a much lower level. 2lO Most reports of symptomatic lung involvement in sickle cell trait are anecdotal. 211 

The diagnostic clinical features of the acute chest syndrome are those of a newly acquired radiographic pulmonary infiltrate associated with fever, cough, chest or bone pain, and hypoxemia. 204-206.212 The pathophysiology of acute chest syndrome is complex and incompletely understood. Contributing factors likely include microvascular stasis and thrombosis by rigid, deformed, polymerized erythrocytes, lung infarction, pneumonia, and thrombotic bone marrow or fat emboli. 204.206.213.214 In some cases the acute chest syndrome may progress to pulmonary edema resembling acute respiratory distress syndrome. 21s

Patients with chronic sickle cell lung disease complain of disabling dyspnea associated with severe hypoxemia, restrictive changes, and reduced carbon monoxide diffusing capacity (DLco) on lung function tests, and pulmonary hypertension with cor pulmonale.216.2l7 Recurrent episodes of acute chest syndrome increase the risk for developing chronic lung disease. 216 Pulmonary hypertension occurs in up to 40% of patients with SCD and is an important risk factor for death, including sudden death. 218 ,219 The pathophysiology of chronic sickle cell lung disease and its relationship to acute lung injury is depicted in Figure 28 . 35. 206 Pathology The pathologic features of sickle cell lung disease are dominated by thrombotic angiopathy including organizing and recanalized thromboemboli, web lesions, and eccentric intimal fibrosis in elastic and muscular arteries ( Fig. 28.36 ).219-222 Thromboemboli in the central pulmonary arteries may be amenable to pulmonary thromboendarterectomy (see also Pulmonary Thromboembolism, above ).223 In some patients with pulmonary hypertension, vascular remodeling may also resemble that seen in primary pulmonary hypertension-concentric intimal fibrosis and plexiform lesions,221.224,22s which have been reported in 60% of autopsied SCD patients. 224 As early as 1936, Yater and Hansmann 226 illustrated cellular intimal thickening of pulmonary arterioles in patients with SCD.

Sickled erythrocytes may focally distend alveolar capillaries, often in association with lobular foci of alveolar septal necrosis, edema, and hemorrhage ( Fig. 28.36A) marrow infarction has been implicated as an important cause of acute chest syndrome and sudden death. 213.214.229 As in other forms of thrombotic pulmonary hypertension, bronchopulmonary anastomoses can be demonstrated between recanalized pulmonary arterial lumina and adjacent bronchial arteries.230 In chronic sickle cell lung disease, the parenchyma is remodeled by patchy interstitial fibrosis (often in a perivascular distribution), healed infarcts, and hemosiderosis ( Fig. 28.37 ).221

Vaso-occlusion in sickle cell disease is initiated by abnormal adherence of polymerized erythrocytes to endothelial cells (Fig. 28.36A) , followed by propagation of the sickle cell thrombus. 231 Mediators that promote the expression of endothelial adhesion receptors include hypoxia, thrombin, tumor necrosis factor, platelet activating factor, and interleukin-l (IL-l). Heightened production of endothelin-l, a potent vasoconstrictor, may also contribute to the acute chest syndrome.232 

A variety of non thrombotic emboli may be encountered in the pulmonary circuit. 233 Various tissues, often disrupted as a result of trauma, gain systemic venous access and embolize to the lung (see Chapter 31) . Some, like bone marrow emboli, are essentially clinically innocuous incidental findings, whereas others (such as amniotic fluid emboli or fat emboli) may cause severe pathophysiologic disturbances.

Certain diseases, notably malignant neoplasms or some parasitic infections, are a source of non thrombotic emboli. Inorganic substances accidentally or purposefully introduced into the systemic veins (e.g., air, pharmaceutical tablet filler materials, medical devices) can embolize to the lungs. Table 28 .8 lists the major categories of nonthrombotic emboli and cites the chapters in which the various entities are primarily discussed.

Pulmonary bone marrow emboli are a frequent incidental histologic finding, reported in 16% of cases in one autopsy series.234.235 Only rarely have pulmonary bone marrow emboli been implicated as a cause of respiratory impairment. 236 ,237 In some cases of sickle cell disease, following bone infarction, large emboli of necrotic bone 1059 marrow along with lipid droplets may embolize to the lung (see Sickle Cell Disease, above). Typically, incidental bone marrow emboli result from traumatic injury or iatrogenic manipulation or compression of bone as in closed-chest cardiac massage or the cutting of ribs at thoracotomy.238 Following cardiac massage, bone marrow emboli may be documented even in the absence of rib fractures,239 Other less common causes of bone marrow emboli include osseous metastases of neoplasms, epileptic seizures, or eclampsia.

Histologically adipose tissue and hematopoietic cells can be identified (see Fig. 31 .20 in Chapter 31). Rarely, as in a case of multiple myeloma, abnormal hematologic cells may be discerned within the embolus. 237 Small particles of bone tissue may also be included. When there has been more extensive osseous trauma, fat emboli may also be documented with oil red 0 stain (see Fig. 31 .17 in Chapter 31).214 Bone marrow emboli are to be distinguished from bone particle emboli following bone marrow transplantation. 240

Megakaryocytes may occasionally be identified among the hematopoietic elements of bone marrow emboli (see above). However, as discussed in Chapter 44, there is a continuous circulation of megakaryocytes from the bone marrow through the lung, where megakaryocytes may frequently be seen in pulmonary capillaries, usually as an incidental histologic finding (Fig. 28.38) . 241 In situations of acute lung injury or disseminated intravascular coagulation (DIe) intrapulmonary megakaryocytes may be greatly increased. In the exudative phase of diffuse alveoc lar damage, the number of megakaryocytes correlates Note: Chapters cited in parentheses are the source of the main discussion in the text. All other entities are primarily discussed in this chapter. *Used for therapeutic embolization. with the number of platelet fibrin thrombi. 242 Histologically megakaryocytes typically appear as deformed, large, lobulated, basophilic nuclei, with little apparent cytoplasm, tightly enclosed within a pulmonary capillary (Fig. 28.38B ).

A variety of other tissues such as brain, liver, adipose tissue, skeletal muscle, and even myocardium may embolize to the lung, usually as a result of extensive soft tissue trauma.243-24~ Adipose tissue emboli are to be distinguished from fat globule emboli, although both types of emboli may be seen in cases of extensive trauma. Brain tissue emboli (see Fig. 31 .21 in Chapter 31) as a result of head trauma should not be confused with embolic or heterotopic brain tissue within the lungs in infants with neurologic malformations such as anencephaly or myelomeningocele, although the source of heterotopic brain tissue in those settings in fact may be embolization occurring in utero or at the time of delivery. Incidental skin emboli, including hair shafts, may result from skin lacerations, repeated venipunctures, or fractures. 249

Tumor embolization, as extensively reviewed in Chapter 44, is an important mode of spread of malignant neoplasms to and within the lungs.2so.2s1 Within the pulmonary vasculature neoplastic emboli incite and are intimately associated with organizing thrombosis and fibrocellular intimal proliferation. 2522s3 In some cases thromboembolic and fibroproliferative pulmonary hyper-tensive changes greatly exceed identifiable tumor emboli, suggesting that tumor cells incite and are then destroyed by the thrombotic process. 2S4 ,2S5 More recently this phenomenon has been termed pulmonary tumor thrombotic microangiopathy. 253, 256, 257 Obliteration of the microvasculature can result in the insidious onset of dyspnea, pulmonary hypertension, and right ventricular failure (subacute cor pulmonale ). 258, 259 The lung at autopsy may simply appear congested, providing little if any macroscopic evidence of massive tumor microembolization. In other cases, tumor emboli may be associated with prominent accentuation of interlobular septa reflecting the development of lymphangitis carcinomatosa. 258 Macroscopic tumor emboli within main or lobar pulmonary arteries are associated most frequently with choriocarcinoma or bulky tumors such as sarcomas, hepatocellular carcinomas, or renal cell carcinomas, which invade the inferior vena cava or its main tributaries. 260 Right-sided cardiac myxoma is an important benign tumor that has been reported to embolize to the lung. 261 The reader is referred to Chapter 44 for a detailed discussion and illustrations of pulmonary tumor emboli.

Release of fat globules into the systemic venous circuit and ultimately the lungs is an important complication of bone and soft tissue trauma or following bone infarction in sickle cell crisis (see above ).262-264 Intravascular fat globules are best recognized by oil red 0 or other lipid stains of frozen lung tissue (see Figs. 31. 16 and 31.17 in Chapter 31). In routinely prepared hematoxylin and eosin (H&E) slides, lipid is dissolved by solvents and the pulmonary capillary bed appears greatly distended by empty vacuoles. In precapillary vessels clear lipid vacuoles displace erythrocytes. Fat embolism is primarily discussed in Chapter 31.

Amniotic fluid embolism and the resultant release of thrombogenic material such as amniotic squames, lanugo hairs, and mucinous substance, is an important complication of pregnancy that can result in respiratory failure, DIC, shock, and death.265.266 The autopsy diagnosis and histologic features of amniotic fluid embolism are covered in detail in Chapter 31.

Trophoblastic emboli to the lungs were first described by Schmorl in 1893 in eclamptic patients. 267 Attwood and Park 267 identified trophoblast emboli in 96 of 220 (44 % ) autopsies of pregnant or parturient women. The mechanism of trophoblast dispersal appears to be uterine contraction, especially in the setting of eclampsia. Trophoblast emboli usually represent incidental findings that do not evoke arterial thrombosis or pulmonary hypertension. They are most readily identified within the first few days of delivery, and dissipate over time. 267 Rare instances of massive trophoblastic pulmonary embolization have been reported to be a cause of death in patients with trophoblastic proliferations such as hydatidiform mole. 268 Fatal trophoblastic embolism not associated with trophoblastic disease is rare. 269 -271 Histologically, cyto-and syncytiotrophoblast cells must be distinguished from those of metastatic choriocarcinoma and from pulmonary megakaryocytes. Compared to megakaryocytes with their large lobulated nuclei, syncytiotrophoblasts contain numerous round to oval nuclei with a coarsely granular chromatin pattern (Figs. 28.38 and 28.39). Immunohisto- chemical staining for human chorionic gonadotrophin or placental lactogen may also help to identify syncytiotrophoblasts. 271 In the case described by Delmis et al., 271 numerous trophoblastic cells obliterated the pulmonary microvasculature and were associated with interstitial pneumonitis.

There have been rare reports of decidua deposited within the lung. The presumed route being decidual embolization. 272 Release of decidua into the maternal circuit has been described in abruptio placentae. 273 However, decidual emboli have not been reported in conjunction with relatively more common trophoblastic emboli. 267 A case of ectopic pulmonary deciduosis has also been hypothesized to represent a variant of stromal endometriosis. 274

Small foreign-body emboli, including birefringent fiberlike material and cotton fibers, are occasional incidental findings in the lungs of patients with intravascular or intra cardiac prosthetic devices, repeated intravenous injections, or chronic indwelling intravenous catheters. 275 ,276 Clinically significant pulmonary foreign-body emboli, however, are most often seen in the context of illicit intravenous drug administration. 277 The most important source of foreign material in this setting derives from the practice of injecting aqueous suspensions of pharmaceutical tablets. 278 Inert tablet filler components that may be identified in the lungs of IV drug users include talc, cornstarch, microcrystalline cellulose, and crospovidone, among others. 279 See Chapter 26 for a complete discussion and description of embolized tablet filler materials, and Chapter 31 for the pulmonary complications of substance abuse.

There have been several reports of pulmonary birefringent microcrystalline emboli in patients receiving total parenteral nutrition (TPN).28°-282 Calcium phosphate has been implicated as the major component of TPN-associated crystalline emboli. In patients with suspected TPNassociated crystalline emboli, it is important to exclude intravenous injection of pharmaceutical tablet suspensions. Patients with indwelling venous access devices may be at risk for illicit use of psychoactive drugs. Tablet components, especially microcrystalline cellulose and talc, are also birefringent, but can be distinguished from calcium phosphate with appropriate histochemical stains and by elemental analysis. 279 Xanthoma-like lipid deposits in the pulmonary capillaries and muscular pulmonary arteries have also been reported in a few pediatric patients on long-term intravenous hyperalimentation supplement (Fig. 28.40 ). 283 Histologically, finely vacuolated histiocytes expand the subintimal zone and constrict the vascular lumen. The lesion is reminiscent of vascular involvement in Gaucher disease, but the two disorders are readily separable by the different clinical scenarios (see Chapter 16) . Lipid-rich hyperalimentation fluid may also predispose to pulmonary vasculitis and deep-seated fungal infections due to Malassezia species (see Fig. 10 .61 in Chapter 10).284 Cholesterol emboli to the lung microvasculature are another rare form of non thrombotic pulmonary embolization, reported in association with aortocaval fistulas. 285 In a well-documented case by Sabatine et al.,285 cholesterol emboli were found in pulmonary and bronchial arteries where they produced marked intimal fibrosis and associated alveolar hemorrhage. Since an autopsy was not performed, the source of cholesterol crystals in that case was not identified. 285 ,286 Atheromatous lesions of the thoracic aorta may rarely be a source of cholesterol emboli to the bronchial arteries (Fig. 28.41 ). In this location, cholesterol emboli may be identified in trans bronchial biopsy specimens.

Large foreign-body emboli including such items as bullets, hypodermic needles (see Fig. 31 .53 in Chapter 31), intravascular catheters, or dislodged vena caval filters, are infrequent occurrences. 287 Numerous other materials such as Teflon, silicone, mercury, barium sulfate (following a barium enema), bile, or even fecal material have rarely gained intravenous access and embolized to the I un gs. 233 ,288-297 Thrombogenic materials such as Gelfoam or polyvinyl alcohol (I valon) used by interventional radiologists to inject bronchial or systemic collateral vessels to control intrapulmonary hemorrhage may sometimes find their way into the small pulmonary arteries (Fig. 28.42A) . 154, 298 The likely route of access of this material is via precapillary systemic-pulmonary arterial shunts. Within the bronchial or other systemic artery, polyvinyl alcohol induces S.D. Groshong et al. thrombosis followed by lumen fibrous obliteration (Fig.  28.42B ).299 Arterial mural destruction and vascular remodeling may effectively extrude the foreign material into the perivascular space. 299 The complications of injected metal coils, also used to promote thrombosis, have been previously discussed (see Pulmonary Artery Aneurysm, above, and Chapter 41).

Air can be introduced into the systemic circulation through traumatic laceration of the large veins of the head and neck, or in the course of a variety of procedures, including transthoracic fine-needle aspiration biopsy (see Chapter 1). Gas bubbles can also form in the vasculature during rapid decompression. In Caisson's disease, small nitrogen bubbles are transmitted into the systemic circulation. Rapid expansion of alveolar gas can also rupture lung capillaries causing injury and gas entry into systemic arteries through the pulmonary veins. The topic of air embolism and the approach to diagnosis at autopsy is discussed in Chapter 31.

A variety of parasites may embolize to the lung as adult worms, ova, or larval forms. Among the nematodes, the larvae of ascaris travel as part of their life cycle via systemic veins to the pulmonary capillaries where they may Among the trematodes, schistosoma ova may embolize to the lungs, producing a foreign-body granulomatous reaction. 302 In patients with pipestem hepatic fibrosis, pulmonary hypertension may result from massive embolization of ova in conjunction with plexiform lesions. Adult flukes rarely embolize to the pulmonary artery. (For a full account of these and other parasites that embolize to the lung, see Chapter 14 on parasitic lung disease.)

Pulmonary venous hypertension (PVH), also known as postcapillary pulmonary hypertension, is defined by a venous pressure in excess of 12mmHg and is the result of obstruction of venous outflow from the lung. Obstruction may be physiologic, the result of decreased cardiac output and increased diastolic pressure due to left ventricular cardiac failure, or have a mechanical basis. The site of obstruction ranges from intrapulmonary, as in pulmonary veno-occlusive disease, to the mitral or aortic valves. A list of causes of PVH is presented in Table 28 .9.

Acute PVH frequently presents as high-pressure pulmonary edema. Chronic PVH not only causes pulmonary edema, but also induces venous, arterial, and parenchymal remodeling, which differs morphologically from that caused by precapillary (arterial) hypertension. The 

Pulmonary edema, which is defined as the abnormal accumulation of extravascular water in the lung, can have many causes, the most important of which are (1) increased intracapillary hydrostatic pressure (i.e., high pressure or cardiogenic pulmonary edema), and (2) loss of integrity of the alveolocapillary membrane (i.e., permeability pulmonary edema)303 (Tables 28.9 and 28.10). High-pressure pulmonary edema is an acute complication of PVH that is most often the result of left ventricular cardiac failure (see below). The prototype of permeability pulmonary edema is the acute respiratory distress syndrome, which is discussed in Chapter 4. Other causes of pulmonary edema for which the pathogenesis is unknown or poorly understood, such as neurogenic pulmonary edema or high altitude pulmonary edema, are also considered in Chapter 4 and listed in Table 28 .10.

In the normal adult, approximately 10 to 20mL of extravascular fluid per hour are removed from the lung via lymphatic drainage. 304 Fluid flux within the lung is governed by intravascular and perivascular hydrostatic and oncotic pressures, according to the Starling equation 304 (Table 28 .11). A low intracapillary hydrostatic pressure and a high oncotic pressure relative to the perivascular space (i.e., interstitial space) favor retention of fluid within the capillary bed. The opposite conditions promote extravascular leakage of fluid. Fluid from the intravascular compartment exits through relatively leaky interendothelial junctions. 304 Pinocytosis across the endothelial cell plays only a minimal role in fluid transit. Within the alveolar interstitium, fluid tracks to lymphatics that originate in the vicinity of the terminal bronchioles. The capacity of the interstitium is about 500mL of fluid versus a volume of about 3000mL in the air-space compartment. 305 ,306 The lymphatics transport fluid out of the lung S.D. Groshong et al. to the ductus lymphaticus and then to the systemic veins. Fluid accumulation that exceeds lymphatic removal initially expands the interstitium in which it is retained by the relatively impermeable tight junctions of alveolar epithelial cells. Upon saturation of the interstitial compartment, alveolar flooding commences. 306 Lymphatic obstruction or reduced plasma oncotic pressure may contribute to pulmonary edema but is rarely its sole cause (Table 28 .10).

The most common cause of pulmonary edema (and PVH) is left-sided ventricular failure, irrespective of its underlying etiology (ischemia, myocarditis, cardiomyopathy, hypertension, etc.). Patients with pulmonary edema are typically anxious and exhibit the symptoms of dyspnea, tachypnea, and orthopnea. On lung auscultation, rales may be heard in the lower lung zones. Wheezing occurs secondary to submucosal edema and narrowing of the airways. Arterial blood gases reveal hypoxemia secondary to shunting of blood through flooded alveolar units and, initially, hypocarbia resulting from hyperventilation. Pulmonary capillary wedge pressure and central venous pressure are elevated. The chest x-ray in the early phase may show Kerley B lines, that is, parallel linear strands extending into the lung from the pleura reflecting edematous interlobular septa (Fig. 28.43A ). Pulmonary arteries are prominent and accentuated in the upper lung zones (cephalization). Alveolar edema is seen radiographically as lower zone or perihilar ground glass infiltrates.

The early phase of interstitial edema is most obviously noted as dilated lymphatics, perivascular clear zones, and widened interlobular septa ( Fig. 28 .43B,q. In the stage of alveolar flooding, the lungs are of increased weight, deep red, and congested. Frothy fluid exudes from the cut lung surface and bubbles out of the airway lumina. Histologically, capillaries are engorged and distended with erythrocytes. Alveolar spaces are filled to a variable extent by eosinophilic hyalinized or slightly vacuolated proteinaceous fluid (Fig. 28.44 ). Occasional intra alveolar 

Qf, net filtration of fluid across endothelial membrane K, filtration coefficient (conductance of fluid across the membrane) Pmv, intracapillary hydrostatic pressure Ppmv, perivascular hydrostatic pressure 0', reflection coefficient (permeability of membrane to protein) ltmv, capillary plasma oncotic pressure ltpmv, perivascular fluid oncotic pressure 

With long-standing pulmonary venous hypertension, as is most often seen in chronic left ventricular cardiac failure or valvular heart disease, significant lung parenchymal and vascular remodeling may occur (congestive vasculopathy).307-309 Virtually any cause of PVH, including extracardiac pulmonary vein obstruction as in fibrosing mediastinitis, may produce similar patterns of lung vascular remodeling. 198 .1 9 9.310-314 Mitral stenosis is an important cause, and serves as a prototype of chronic PVH. 315 

The clinical features of congestive vasculopathy vary according to the underlying cause of PVH. In mitral stenosis the clinical profile includes dyspnea, orthopnea, wheezing, and hemoptysis. Rales and rhonchi may be prominent, but frequently there are no audible findings in the lungs. Chest x-ray findings may include cardiomegaly, pulmonary venous engorgement, and pulmonary edema. Typically pulmonary function tests indicate restriction, with reduced lung volumes and reduced DLco. Arterial blood gas values often show borderline or low peo2 and mild resting hypoxemia,3J8,319

The lung parenchyma in congestive vasculopathy appears deep red-brown and is firm to palpation (brown induration) (Fig. 28.45) . Histologically, alveolar and interlobular septa are fibrotic with increased collagen and reticulin fibers (Fig. 28.46 ).320 Alveolar capillaries are dilated and congested with accentuated capillary profiles that may be so numerous as to simulate capillary hemangiomatosis (see below).321.322 Numerous hemosiderinladen macrophages (heart failure cells) are typically present in alveolar and interstitial compartments ( stage it may be difficult to distinguish arteries from veins other than by location (i.e., veins in the interlobular septa, arteries adjacent to airways). As in acute pulmonary edema, lymphatic channels are dilated, and lymphatic vessels have thick walls. 308.33o Venous hypertension is transmitted through the capillary bed to the pulmonary arteries, which may also undergo extensive remodeling?24 Medial hypertrophy with extension of muscle into arterioles (<100)..lm diameter) may be prominent. Paradoxically, the degree of medial hypertrophy may be disproportionately severe for the level of pulmonary hypertension and exceed the venous changes, a phenomenon that is not well explained.307.324 Varying degrees of intimal fibrosis, mainly eccentric fibrosis, but sometimes concentric fibrosis, may involve long stretches of the pulmonary artery ( Fig.  28.49 ). Arterial intimal fibrosis is more common in the upper lobe, whereas medial hypertrophy is generally more severe in the lower lobe. Concentric intimal fibrosis lacks the laminar appearance seen in idiopathic pulmonary hypertension. Adventitial fibrosis also is typically present, but plexiform and dilatation lesions and arterial necrosis are rare or absent.

Patients with PVH are treated by addressing the underlying etiology. In the most common scenario of left ventricular failure, this is achieved by optimizing the medical management of the underlying congestive heart failure. In cases where surgical intervention is possible, such as valvular disease, there is a rapid fall in pulmonary pres- sures, despite persistence of the arterial medial hypertrophy and intimal fibrosis. The rapid improvement appears to be the result of elimination of edema from the vessel walls and interstitium. Pulmonary vascular findings may persist even after clinical resolution of the venous hypertension. Rarely, complete regression of the histologic lesions has been observed.

Pulmonary veno-occlusive disease (PVOD) is a rare cause of pulmonary hypertension, accounting for approximately 10% of all cases classified clinically as primary pulmonary hypertension, with an estimated annual incidence of 0.1 to 0.2 cases per million persons. [331] [332] [333] The disease may present at any age, but typically is seen in children and young adults. Adult cases show a male predominance (male-to-female ratio of 2: 1), while childhood cases show no sex predilection. The disease may present with an acute flu-like pneumonia, or slowly progressive exertional dyspnea and fatigue. 334 As the disease progresses, there are increasing symptoms of right-sided heart failure, including exertional syncope, chest pain, cyanosis, and hepatosplenic congestion. Since these symptoms are also typical of primary pulmonary hypertension, there can be significant diagnostic confusion in these cases. Pleural effusions are commonly seen in patients with PVOD, while they are rare among patients with primary pulmonary hypertension. Similarly, hemoptysis, an unusual symptom in primary pulmonary hypertension, may occur in patients with PVOD, but is rarely massive. 335 Radiologically PVOD may be suspected with a combination of a normal-sized left atrium, normal left-sided heart valves, a normal ejection fraction, normal-sized major pulmonary veins, yet enlarged pulmonary arteries. Kerley B lines and changes suggesting edema without shunting to the upper lobes may be seen. The wedge pressure is usually normal or low in patients with PVOD and is not elevated as is the case in congestive heart failure. Following injection of saline, the pressure curve shows immediate elevation that tapers to normal or low pressures as the collateral flow drains away the increased pressure. Extrapulmonary vein obstruction would lead to a persistently elevated pressure, as all vessels are equally involved. 336 There have been isolated reports of PVOD as a cause of sudden death in both adults and infants. 337 ,338 It appears that PVOD is a common pattern of injury from a wide variety of etiologies, Chemical and pharmaceutical exposures have been associated with the development of PVOD in a number of cases, Drugs with the highest association with PVOD include bleomycin, mitomycin, and carmustine,339 Additionally, some have suggested a greater risk in the setting of bone marrow transplantation, as opposed to cytoreductive chemotherapy,340 Other causes of PVOD include viral infection, toxins, radiation, autoimmune disease, and pregnancy.333,341 A few familial cases have also been described. 342

Relatively little is known about the mechanism for development of pvon It is hypothesized that the disease process is initiated by endothelial damage, either through direct toxicity as in the case of drug exposure, or immunemediated injury, perhaps secondary to infection, Since thrombotic occlusion of pulmonary veins is often seen, thrombotic diathesis has also been invoked as a part of the mechanism of pvon However, many cases of PVOD do not show evidence of pulmonary venous thrombosis or recanalization. Therefore, thrombosis may be a secondary phenomenon, rather than an initiating event in the development of this disease.

Pulmonary veno-occlusive disease is a challenging diagnosis, particularly in adult patients. Pediatric populations do not have the complicating findings of age-related changes and chronic heart failure.

Pulmonary veno-occlusive disease is a disease process of small veins and venules, with occasional involvement of the larger veins of the hilum. Most cases of PVOD have widespread bilateral parenchymal lesions that consist of areas of venous congestion, or venous infarction (Figs. 28.50 and 28.51) . Venous infarcts are characterized by ischemic necrosis of tissue at the periphery of the pulmonary lobule with preservation of the central portion of the lobule, where the best oxygenated blood is able to sustain the tissue (Fig. 28.51 ). These infarcts are distinct from the wedge-shaped arterial infarcts seen in cases of embolic disease. Veins can best be appreciated as they approach and drain into the interlobular septum. The process is characterized by intimal fibrosis within pulmonary veins traversing the interlobular septa ( Fig.  28.52A,B) . The fibrosis is variably dense, and can appear very loose and edematous. The venous lumen is narrowed or occluded, and may show localized thrombosis, or evidence of recanalization. The occlusion of veins may be partial or complete, and have variable cellularity ranging from cellular and spindle-like to overtly hyalinized, as seen in cases of old organized thrombus (Fig. 28.53 ). Over time, veins may become arterialized with additional elastic fibers and abundant smooth muscle creating distinct internal and external laminae, and may be confused with pulmonary arteries if the anatomic location is not properly identified (Fig. 28.52C ).

Arteries and arterioles may show mild medial hypertrophy.343 Similar to the venous lesions, half of cases show some degree of intimal fibrosis in arteries. While the mechanism of arterial intimal fibrosis may be similar to the venous lesions, the arteries usually appear less affected. Occasionally arterial occlusive lesions are severe. 343 Arterial thrombosis and recanalization is common, but no plexiform, necrotizing, or dilated arterial lesions are present. The presence of arterial thrombosis is a feature of veno-occlusive disease that is not shared with other forms of pulmonary venous hypertension. Lymphatics are often markedly dilated and can give the appearance of lymphangiomatosis (Fig. 28.52D) .

The surrounding lung parenchyma has prominent edema, and may show evidence of chronic hemorrhage, such as hemosiderin-laden macrophages, interstitial hemosiderosis, or interstitial fibrosis. Iron encrustation (otherwise known as endogenous pneumoconiosis) may be seen in cases of PVOD as the result of long-standing chronic hemorrhage into the interstitium. Foreign-body giant cells may be present, and the overall process may be confused with asbestosis or other pneumoconioses, or chronic aspiration (see Chapter 21) . The presence of interstitial thickening centered on the interlobular septum can be a very useful pattern in diagnosing PVOo. 336 There can be dilation of capillaries within the fibrosis, or if collapsed, the endothelial cells can appear similar to lymphocytes and mimic a cellular interstitial pneumonia (Fig.  28.52E ) . There may be striking patches of pulmonary capillary congestion and distention, often with a nearby thickened vein (Fig. 28.53 ). These areas of congestion are the result of adjacent venous occlusion, although the discrete area of occlusion may not be present within the section, and may require step-sections for identification. In addition to the congestion of capillaries, there may be proliferation of capillaries within areas of fibrosis in an attempt at collateralization. Furthermore, these vessels can extend around arteries and veins, into their walls or in the thickened intima.

Often cases with extensive capillary proliferation, especially into the vascular adventitia, raise the diagnos- tic dilemma of primary PVOD versus pulmonary capillary hemangiomatosis (PCH) (see below). Many believe that PCH may in fact represent one of the patterns of primary PVOD rather than a distinct diagnostic entity. The two entities share the same age demographics, poor prognosis, and many of the same histologic findings, suggesting that the two diseases have more similarities than differences.

Pulmonary veno-occlusive disease remains a difficult diagnosis, and is likely underdiagnosed. The mixed histologic presentation of PVOD can easily be confused with entities such as hemangiomatosis, cellular interstitial pneumonia, vascular neoplasms of the lung, hemosiderosis due to heart failure, Goodpasture's disease, chronic passive congestion, Iymphangiomatosis, or pulmonary hypertension. The prevalence of congestive heart failure and associated hemosiderosis makes the diagnosis especially challenging in the adult population. Pediatric cases often present with a more straightforward histologic appearance and therefore many pediatric pathologists are more aware of the condition and are more comfortable making the diagnosis.

Treatment with vasodilators, anticoagulants, and immunosuppressive agents has met with limited success. While vasodilators have improved survival considerably in pulmonary arterial hypertension, there are conflicting data on their application in PVOD, including reports of massive pulmonary edema and death. 344 Like other patients with pulmonary hypertension, PVOD patients are usually treated with anticoagulation unless there is a history of significant hemoptysis. However, there have not been studies to document benefit in patients specifically with a diagnosis of PVOD. Steroids and other immunosuppressants have had only scattered anecdotal reports of success. 345 Overall, prognosis remains poor, with most patients dying within 2 years of diagnosis, unless lung transplantation is undertaken. 346 There are no reports of recurrence after lung transplantations.

Pulmonary capillary hemangiomatosis (PCH) is a locally aggressive vascular proliferation of capillary-like vessels that is a rare cause of pulmonary hypertension. The entity was first described in a 71-year-old woman and has since been encountered in patients ranging in age from 6 to 71 years, but most occurring in the 20-to 40-year age group.347-349 It is recognized to occur in congenital, familial, and sporadic forms. Congenital PCH often occurs in association with other developmental abnormalities, and has been known to cause significant proximal occlusion of the airways.35o The familial form has an autosomal recessive inheritance pattern, and appears to be very rare with only a single documented affected family. 351 The more common spontaneous form of the disease typically presents in young patients with the onset of symptoms stereotypic for pulmonary hypertension. Often these cases are initially diagnosed as primary pulmonary hypertension or pulmonary veno-occlusive disease. The presence of hemoptysis or pleural effusion should raise suspicion for the possibility of PCH. When clinically suspected, the lesion is typically diagnosed via pulmonary angiography. Biopsy is rarely undertaken, and can result FIGURE 28 .54. Pulmonary capillary hemangiomatosis (PCH). A. Low-power view of PCH demonstrates the patchy septal thickening by a proliferation of capillary-sized structures. A clue to this disease is the low-power appearance of patchy "conges-1071 in massive hemorrhage. Therefore, the histologic findings are often only seen at autopsy Pathogenesis While PCH has been considered by some to represent a low-grade vascular neoplasm, most consider the lesion to be a benign vascular proliferation in response to either an infectious agent, such as Mycoplasma pneumoniae, or inflammation due to an underlying collagen vascular disease. 347 ,352.35 3 The typical symptoms of hemoptysis and hemorrhagic pleural effusion are secondary to vascular invasion within bronchioles, air spaces, and the pleura. The mechanism of the associated pulmonary hypertension, however, has remained elusive. Current theories include vascular obliteration by capillary growth, in situ thrombosis, and hypoxic pulmonary vasoconstriction. 354 There has been a report of a case of PCH without pulmonary hypertension. 355 In this patient, there was significant alveolar and bronchiolar capillary proliferation, but no proliferation within vessel walls. Therefore, it seems likely that vascular compression by adjacent capillary proliferation may be the dominant mechanism of pulmonary hypertension in PCH.

Pulmonary capillary hemangiomatosis is characterized by interstitial proliferation of small, engorged capillarysized vascular channels, often in a vaguely lobular and patchy distribution (Fig. 28.54 ). Vascular proliferation occurs around the bronchovascular bundle, as well as throughout the alveolar septa and pleura. Sometimes the tion." B. Higher magnification shows the proliferation of capillary structures within the septa (many more than the typical single-capillary thickness seen in normal septa). FIGURE 28.55. Pulmonary capillary hemangiomatosis. A. Septal thickening due to capillary-like proliferation and endothelial hyperplasia, mimicking interstitial pneumonia. B. CD31 immuengorgement is associated with thick-walled central or eccentric vessels. Endothelial cells are cytologically bland. Venous infiltration by capillary-sized channels is associated with intimal fibrosis and secondary veno-occlusive disease. The alveolar septa are typically expanded creating possible confusion with interstitial pneumonia (Fig.  28 .55A). Therefore, it is critical to recognize the vascular nature of the disease. The vascular channels stain with the usual endothelial markers such as CD31, CD34, and factor VIII-related antigen (Fig. 28.55B) . Frequently, there are increased numbers of hemosiderin-laden macrophages in air spaces, presumably from microvascular hemorrhages. True interstitial fibrosis with collagen deposition may be seen in cases with significant hemosiderosis.

A secondary pulmonary hypertensive change is reported that involves thickening of the walls, both medial hypertrophy and fibrointimal proliferation, but not the more severe degrees of pulmonary hypertension, specifically necrotizing, plexiform, or dilatation lesions. Vascular tumors or proliferations have not been described outside the lung in these patients.

There is considerable overlap in the histologic manifestations, clinical presentation, and prognosis of pulmonary veno-occlusive disease and of pulmonary capillary hemangiomatosis. This has led many to question whether PCH is a true diagnostic entity, versus a manifestation of primary pVOD.336

Overall, the prognosis of the disease is poor, with a median survival of 3 years from time of diagnosis. To date, S.D. Groshong et al. nohistochemical staining highlights the numerous endotheliallined, thin-walled capillary-sized spaces within the alveolar septa.

there have been a few reported cases of successful treatment or stabilization of disease using interferon-a-2a, again suggestive of a possible role of inflammation?54 Epoprostenol, a common therapy in PPH, is contraindicated for PCH because it may lead to the development of pulmonary edema. Otherwise, lung transplantation remains the only alternative. While there are no reported cases of PCH recurring in a single transplanted lung, there is a report of PCH rapidly developing de novo following a double lung transplant. 356

Hypoxia is a potent vasoconstrictor of pulmonary arteries. 357 The constrictive nature of hypoxia within the lung exerts both a positive and a deleterious effect. Hypoxic vasoconstriction shunts blood to better ventilated lung zones, thereby improving ventilation-to-perfusion matching and maintaining blood oxygen tension. On the other hand, chronic hypoxia causes vascular remodeling and sustained pulmonary hypertension, leading to cor pulmonale. l2l Hypoxic vasoconstriction may occur in situations of alveolar hypoxia or hypoxemia of mixed venous blood. 357 • 358 Acidosis potentiates the constrictive effect of hypoxia. 357 The clinical situations in which hypoxic vasoconstriction develops can be broadly categorized as follows: (1) reduced ambient levels of inspired oxygen, as experienced at high altitude; (2) conditions of hypoventilation including chest wall or diaphragmatic muscle weakness, obesity, and central hypoventilation; (3) deformities of the thoracic cage, as in severe kyphoscoliosis; (4) mechanical airway obstruction, as with tumor, an aspirated foreign body or obstructive sleep apnea; (5) chronic obstructive airways disease (e.g., emphysema and chronic bronchitis); and (6) other lung disorders associated with hypoxemia. The hypoxia of high altitude, kyphoscoliosis, and obstructive sleep apnea are considered in detail below. The histopathologic features of hypoxic pulmonary hypertension, however, are similar regardless of the cause of hypoxia. 12l ,359

Terrestrial hypoxia not only causes pulmonary hypertension in individuals who live at higher altitudes, but also is important to the thousands of individuals who transiently ascend to higher altitudes for recreational purposes of traveling, trekking, and mountain climbing. 360 Dwellers at high altitude, such as in the Peruvian Andes or the Tibetan plateau, develop elevated pulmonary artery pressure, and experience an increased incidence of congenital heart defects as well as hyperplasia and tumors of the carotid body.360 Individuals who rapidly ascend to high altitude from the lowlands may experience high-altitude pulmonary edema, as discussed in Chapter 4. Some long-term dwellers at high altitude may suffer a fulminant form of pulmonary hypertension and cor pulmonale referred to as chronic mountain sickness or Monge disease. 36o ,361

Residents of altitudes higher than 3000m have, on average, a resting pulmonary artery pressure greater than that of residents at sea level. l21 This difference is accentuated upon exercise. The effect of high altitude is variable among individuals, but there is evidence that vascular remodeling affects a greater proportion of individuals as altitude increases. 121 It is also probable that popUlations that have lived at high altitude for generations have genetically adapted to their environment. 121 ,362 The condition of chronic mountain sickness was first described in 1928 by Monge 363 and beautifully summarized by Saldana and Arias-Stella 360 as a condition of extreme cyanosis, erythrocytosis, central nervous system (CNS) symptoms, hypoxemia «70% O2 saturation), excessively elevated pulmonary artery pressure, and right heart failure. The most important treatment for patients with Monge disease is descent to a lower altitude.

Sleep apnea syndrome is a relatively common condition of repeated apneic events occurring during sleep, resulting in episodic severe hypoxia and hypoxemia. 3 64-367 Sleep apnea has been divided into central sleep apnea caused by defective neurologic control of breathing, in which there is absence of both respiratory efforts and airflow, and obstructive sleep apnea due to excessive pharyngeal 1073 adipose and other soft tissues, in which there is increased respiratory efforts despite partial or complete occlusion of the upper airway.364-367 Obstructive sleep apnea is frequently associated with obesity.368-372 The constellation of obesity, sleep apnea, hypersomnolence, and hypercarbia was designated by Burwell et al. 373 as the Pickwickian syndrome, after Dickens' novel, The Pickwick Papers, which has the minor character of Joe the fat boy, who exhibits many of the features of obstructive sleep apnea. 374 Patients with obstructive sleep apnea frequently manifest nocturnal restlessness and snoring, are often hypertensive, may develop severe cor pulmonale due to sustained pulmonary hypertension, and have an increased risk of stroke, coronary artery disease, and sudden death. 368 ,374-376 The cause of pulmonary hypertension in obstructive sleep apnea is complex, and probably multifactorial. 377 Generally mild pulmonary hypertension has been shown to occur in the absence of underlying lung disease,376,377 Left ventricular dysfunction with pulmonary venous hypertension or obesity appears to be an important contributing factor in many patients. 377 -379 Using echocardiography, Guidry and colleagues 380 showed that patients with sleep-disordered breathing (SDB) had a small but significant increase in right ventricular wall thickness compared to a control population without SDB.

Pulmonary hypertension and cor pulmonale have long been associated with severe spinal deformities that distort the dimensions of the thoracic cage and constrict the lungs. 381 Pulmonary function tests in patients with kyphoscoliosis are characterized by reduced lung volumes, ventilatory flow rates, and diffusing capacity. Arterial blood gases show hypercapnia and hypoxemia due to the small volume of lung that is ventilated. 382 The onset of pulmonary hypertension and cor pulmonale is a poor prognostic sign that frequently heralds death. Pulmonary hypertension tends to occur in those patients who develop hypoxemia. 381 ,383 Pathophysiology and Pathologic Features of Hypoxic Pulmonary Hypertension Hypoxia exerts its effects mainly on the small muscular pulmonary arteries and precapillary nonmuscular arterioles, but the mechanism of hypoxic vasoconstriction and vascular remodeling is complex and not completely understood. 384 Hypoxia profoundly affects the vascular endothelium to release vasoconstrictive and proliferative mediators. Chronic hypoxia promotes muscle and fibroblast proliferation as well as extension of smooth muscle FIGURE 28.56. Hypoxic vasculopathy. A. Muscularization due to chronic hypoxia in a patient with obstructive sleep apnea. The normally nonmuscularized arteriole has a well-developed musinto nonmuscularized vessels, probably by acting on pericytes and intermediate cells in the vascular wal1. 385 A loss of vessels has also been identified in experimental animals, although recent reports suggest that increased vascularity occurs through hypoxia-induced angiogenesis. 38 6-388 Other mechanisms of vascular remodeling in hypoxia may include release of mitogenic stimuli from smooth muscle cells, endothelial apoptosis, elevated levels of angiotensinconverting enzyme (ACE), inflammatory mediators (IL-8, IL-6), and reactive oxygen species. 384 Modulators such as endothelin-l, vascular endothelial growth factor, angiotension II, and nitric oxide have also been implicated in hypoxic vascular remodeling. 389 .390 The increase in mitogenic factors has been proposed to occur through the regulation/induction of various transcription factors such as hypoxia-inducible factor-l (HIF_l).384 Additionally, hypoxia contributes to pulmonary hypertension indirectly by promoting vasoconstriction and increased shear stress. 384 The pathologic features of hypoxia-induced pulmonary hypertension are similar among the various predisposing conditions. 121,359 The effects of hypoxia on the pulmonary trunk and main pulmonary arteries are well seen in dwellers of high altitude. The studies of Saldana and Arias_Stella360. 391 .392 indicate a greater medial thickness and persistence of the aortic configuration of thick, continuous elastic fibers in the central pulmonary arteries in individuals born and raised at high altitude. In general, the main histologic manifestation of chronic hypoxia in parenchymal vessels is muscularization of arterioles, with development of distinct internal and external elastic laminae, and a medial muscle coat that sometimes extends into vessels as small as 30 to 40!lm (Fig. 28.56A,B) . [393] [394] [395] Medial hypertrophy of larger muscular arteries may also be seen, but frequently muscularization of arterioles is associated with normal or minimally altered muscular arteries. l2l ,359.395,396 Autopsy data in patients with Monge disease are limited; however, one study showed hypermuscularization of small pulmonary arteries above that normally seen in dwellers at similar altitude. 360 Another general feature of hypoxic vasculopathy is longitudinally oriented smooth muscle bundles within the intima of muscular pulmonary arteries, although intimal fibrosis tends to be mild (Fig. 28.57 ).121.359,396 Pulmonary veins may also show excessive smooth muscle of a lesser degree than that seen in arteries. 397 Although the capillary network is usually described as normal, in some patients with severe sleep apnea syndrome and right ventricular hypertrophy extreme capillary proliferation and hemosiderosis may be seen FIGURE 28,57. Hypoxic arterial remodeling in a patient with severe kyphoscoliosis. Note concentric intimal thickening with longitudinally oriented muscle bundles. (Fig. 28.56C ).394The degree of capillary proliferation may simulate that seen in pulmonary capillary hemangiomatosis (see above), the key distinction being the absence of capillary infiltration of vessels and veno-occlusive-like changes. The cause of this proliferation is not completely determined, but it likely relates to concomitant left ventricular cardiac failure or possibly a direct angiogenic effect of hypoxia on the capillary bed.

Pathologic features of patients with kyphoscoliosis include small, distorted lungs.383.398 In a quantitative study, Davies and Reid 398 documented fewer numbers of alveoli that were irregularly emphysematous or atrophic. In patients with cor pulmonale, medial hypertrophy of muscular pulmonary arteries with extension of muscle into arterioles has been reported. 383.398 The carotid body, an oxygen-sensing chemoreceptor organ, undergoes hyperplasia in the setting of chronic hypoxia both in humans and animals living at high altitude, and in various hypoxic pulmonary conditions such as cystic fibrosis, cyanotic congenital heart disease, sleep apnea syndrome, and emphysema.399. 

Interstitial Pulmonary Fibrosis Patients with interstitial fibrosis, such as idiopathic pulmonary fibrosis, frequently develop cor pulmonale as a result of pulmonary hypertension (see Chapter 19) . 402 In areas of interstitial fibrosis, muscular pulmonary arteries exhibit changes of medial hypertrophy and concentric or eccentric intimal fibrosis (Fig. 28.58 ). Longitudinally oriented intimal smooth muscle with extension of muscle into peripheral arterioles has also been reported. 403 The arterial changes are similar, regardless of the cause of interstitial fibrosis.403 Pulmonary veins also develop hyalinized fibrosis. The pulmonary capillary bed is greatly reduced and the distance between capillary and epithelial basement membrane is increased, limiting the diffusion of oxygen and carbon dioxide. Bronchial arteries are often hypertrophied with increased bronchopulmonary anastomotic shunts. 403 The mechanisms responsible for vascular changes in interstitial fibrosis include injury and remodeling secondary to the surrounding chronic inflammation and fibrosis with obliteration and restriction of the vascular bed. 404 Hypoxia may also contribute to vasoconstriction. 402 Since the vasculature in the nonfibrotic areas may be normal, the presence or absence of pulmo-1075 FIGURE 28.58. Idiopathic pulmonary fibrosis. Severe concentric intimal fibrosis of a muscular pulmonary artery in region of advanced honeycombing. nary hypertension is dependent on the overall extent of fibrosis.

The pulmonary vascular lesions in diffuse alveolar damage are progressive, vary with the stage and duration of the parenchymal disease, and reflect the evolution of vascular remodeling in this rapidly unfolding form of alveolar injury and fibrosis (see Chapter 4) . 405 In the exudative phase macroscopic or microscopic thrombi are seen along with hypoxic vasoconstriction. 406 The capillary bed, as assessed by vascular injection studies, is extensively obliterated. 407 Thromboemboli, most likely representing in situ thrombosis, have been identified in 95% of lungs studied by vascular injection at autopsy.406,408 Both macrothrombi, in elastic and large muscular pulmonary arteries, and micro thrombi in small arteries and arterioles may be identified. 406 In the proliferative phase, medial hypertrophy and eccentric or concentric intimal fibrosis are characteristic. Arterial and venous lumina are narrowed by layered fibrin, proliferating myointimal cells, hyperplastic endothelial cells, and fibromyxoid connective tissue ( 

Pulmonary hypertension is the major cardiovascular complication of chronic obstructive pulmonary disease FIGURE 28.59 . Diffuse alveolar damage. Fibromyxoid intimal proliferation of muscular pulmonary artery in proliferative phase diffuse alveolar damage (DAD). Note also medial hypertrophy and adventitial fibrosis. The adjacent lung parenchyma is totally effaced by confluent air-space fibrosis. (Movat.) (COPD).41O The vascular changes in emphysematous lungs are thought to be the result of chronic hypoxia. 410 In patients with stable COPD, severe pulmonary hypertension (>40mmHg) occurs in fewer than 5% of patients. 4l1 A significant proportion of patients with severe pulmonary hypertension have additional causes such as cardiac disease, obstructive sleep apnea, or appetite suppressant history. Chaouat and colleagues,4l1 in a large cohort of patients with COPD, found severe pulmonary hypertension without causes other than COPD in only 1.1 % of patients overall and in 41 % of patients with COPD and severe pulmonary hypertension. Patients with COPD as the only detectable cause of severe pulmonary hypertension typically had hypercapnia, very low DLco, severe exertional dyspnea, and a short life expectancy. 411 Early morphologic studies noted a well-developed muscular coat in small pulmonary arteries, indicative of peripheral extension of muscle, in patients with right ventricular hypertrophy.410.4 12 Longitudinal intimal muscle fibers and mild intimal fibrosis were also noted; however, the medial thickness of larger muscular arteries was found to be norma1. 410 . 412 On the other hand, Naeye and Greenberg 413 found increased medial thickness in endstage pan acinar emphysema due to <Xl-antitrypsin deficiency. Magee et a1. 414 correlated vascular changes with morphologic severity of emphysema and found increased intimal thickness (compared to nonsmoker control lungs ) in all emphysema groups, and medial hypertrophy associated with severe emphysema. Hale and colleagues 415 emphasized the importance of cigarette smoke as a possible independent contributor to medial and intimal thickening. The destruction of the pulmonary capillary bed, which may be extensive in emphysema, is not S.D. Groshong et al. considered to be a main factor in the production of pulmonary hypertension.12l·416. 417 Dunnill's416 suggestion of compression of pulmonary arteries by emphysematous air spaces has not been given serious consideration in more recent studies.

Liebow,418 using the vinylite cast technique, described expansion of the bronchial arterial circulation as well as marked enlargement of the bronchopulmonary venous system in advanced emphysema. Collaterals between bronchopulmonary and pulmonary veins theoretically represent a source of right to left shunt.

Lung biopsy specimens in the evaluation of pulmonary vascular disease

Classifying pulmonary vascular disease

Pulmonary hypertension

The pathology of hypertensive pulmonary vascular disease. A description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects

Third World Symposium on Pulmonary Arterial Hypertension in Venice

Chicago: Year Book Medical Publishers

Systemic-topulmonary blood supply in tetralogy of Fallot with pulmonary atresia

The developing bronchial arteries in a fetus of the twelfth week

Growth and development of the respiratory system-anatomical development

Pulmonary hypertension in congenital malformation of pulmonary vessels

Congenital unilateral absence of a pulmonary artery. The importance of flow in pulmonary hypertension

Absent right pulmonary artery

Anomalous collateral from the coronary artery to the affected lung in a case of congential absence of the left pulmonary artery. Effect on coronary circulation

Chronic thromboembolic occlusion in the adult can mimic pulmonary artery agenesis

Physiologic studies in congenital absence of the left main pulmonary artery

Congenital unilateral absence of a pulmonary artery: a report of two adult cases

Congenital absence of the right pulmonary artery

Pathology of the pulmonary circulation before and after correction of low flow states

Vascular changes in pulmonic stenosis and tetralogy of Fallot studied in lung biopsies

The pulmonary arterial tree in pulmonic atresia

A hitherto unrecognized tendency to the development of widespread pulmonary vascular obstruction in patients with congenital pulmonary stenosis (tetralogy of Fallot)

The aetiology of pulmonary thrombosis in cyanotic congenital heart disease with pulmonary stenosis

Collateral circulation to the lungs in congenital pulmonic stenosis

Postoperative pulmonary hypertension in tetralogy of Fallot

Medial defects of lung vessels: a new cause of pulmonary hypertension

Misalignment of lung vessels: a syndrome causing persistent neonatal pulmonary hypertension

Combined therapy with inhaled nitric oxide and intravenous prostacyclin in an infant with alveolar-capillary dysplasia

Congenital alveolar capillary dysplasia-an unusual cause of respiratory distress in the newborn

Misalignment of lung vessels and alveolar capillary dysplasia: a cause of persistent pulmonary hypertension

Congenital alveolar capillary dysplasia: a developmental vascular anomaly causing persistent pulmonary hypertension of the newborn

Persistent pulmonary hypertension of the newborn due to alveolar capillary dysplasia

Early pulmonary vascular changes in congenital heart disease studied in biopsy tissue

Normal pulmonary and bronchial vasculature

Pulmonary hypertension in left to right cardiac shunts

Primary pulmonary hypertension

Pulmonary hypertension in congenital heart disease

Pulmonary arteries in congential heart disease: A structure-function analysis

Hypertensive pulmonary arterial lesions as a late result of anastomosis of systemic and pulmonary circulations

Pulmonary vascular disease complicating the Blalock-Taussig anastomosis

Pulmonary vascular disease after systemic pulmonary arterial shunt operations

Executive summary from the World Symposium on primary pulmonary hypertension

Third World Symposium on Pulmonary Arterial Hypertension in Venice

One hundred years of research in the pathogenesis of pulmonary hypertension

American College of Chest Physicians Consensus Statement

Pathophysiology of cor pulmonale in chronic obstructive pulmonary disease. Part One

World Health Organization. Chronic cor pulmonale. A report of the expert committee

Ventricular weight in cardiac hypertrophy

Primary pulmonary hypertension: a national prospective study

Pulmonary arterial hypertension in children

The clinical course of cardiac disease in Down's syndrome

The pulmonary vascular bed in children with Down's syndrome

Pulmonary changes in congenital heart disease with Down's syndrome: their significance as a cause of postoperative respiratory failure

Expression of human herpes virus 8 in primary pulmonary hypertension

Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri

Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma

Induction of pulmonary hypertension by an angiopoietin 1ITIE2/serotonin pathway

ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells

The pathobiology of pulmonary hypertension

Gene expression patterns in the lungs of patients with primary pulmonary hypertension: a gene micro array analysis

Peroxisome proliferation-activated receptor gamma (PPARgamma) expression is decreased in pulmonary hypertension and affects endothelial cell growth

Changing concepts of the pulmonary plexiform lesion

Genetic anticipation and abnormal gender ratio at birth in familial primary S.D. Groshong et al. pulmonary hypertension

Heterozygous germline mutations in a TGF-beta receptor, BMPR2, are the cause of familial primary pulmonary hypertension

Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF family

Pulmonary hypertension associated with connective tissue disease

The pulmonary pathologic manifestations of the CREST syndrome

Mixed connective tissue disease

Primary and secondary pulmonary hypertension in systemic lupus erythematosus

Pulmonary hypertension in collagen vascular disease

Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infections

Imbalance between platelet vascular endothelial growth factor and platelet derived growth factor in pulmonary hypertension

Vascular endothelial growth factor in pulmonary hypertension

Plasma coagulation profiles in patients with severe primary pulmonary hypertension

Coagulation and fibrinolytic profiles in patients with severe pulmonary hypertension

Portopulmonary hypertension: a tale of two circulations

Primary pulmonary hypertension and cirrhosis: are they related?

Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics

Enhanced synthesis and reduced metabolism of endothelin-1 (ET-1) by hepatocytes-an important mechanism of increased endogenous levels of ET-1 in liver cirrhosis

Altered endothelin homeostasis in patients undergoing liver transplantation

Primary pulmonary hypertension in HIV infection

Human immunodeficiency virus infection and pulmonary hypertension: two new cases and a review of 86 reported cases

Primary pulmonary hypertension in HIV patients: a systematic review

Primary pulmonary hypertension in association with human immunodeficiency virus infection: a possible viral etiology for some forms of pulmonary arteriopathy

Platelet derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients

Potent stimulation of monocyte endothelin-1 production by HIV-1 glycoprotein

Expression of endothelin-1 in lungs of patients with pulmonary hypertension

Primary pulmonary hypertension in HIV infection. An outcome determined by particular HLA class II alleles

Valvular heart disease associated with fenfiuramine-phentermine

Aminorex to fen/phen. An epidemic foretold

Fatal pulmonary hypertension associated with short-term use of fenfiuramine and phentermine

Autopsy findings of heart and lungs in a patient with primary pulmonary hypertension associated with use of fenfiuramine and phentermine

Complex vascular lesions at autopsy in a patient with phentermine-fenfiuramine use and rapidly progressing pulmonary hypertension

Fenfiuramine and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension

Hyperplasia of pulmonary artery smooth muscle cells is causally related to overexpression of the serotonin transporter in primary pulmonary hypertension

Aminorex and the pulmonary circulation

Aminorex and pulmonary hypertension: a review

Dexfenfiuramine and primary pulmonary hypertension

Toxic oil syndrome: survival in the whole cohort between 1981 and 1995

Clinical and pathologic manifestations of pulmonary vascular disease in the toxic oil syndrome

An epidemic of pulmonary hypertension after toxic rapeseed oil ingestion in Spain

Pulmonary artery medial hypertrophy in cocaine users without foreign particle microembolization

Pulmonary hypertension associated with long-term inhalation of 'crank' methamphetamine

Pulmonary hypertension and foreign body granulomas in intravenous drug users

Clinical toxicity of cocaine adulterants

Phenytoin toxicity from smoking crack cocaine adulterated with phenytoin

Pulmonary vascular abnormalities in cocaine users

Pulmonary hypertension in a patient with tryptophan-induced eosinophilia-myalgia syndrome

Pulmonary disease associated with L-tryptophan-induced eosinophilic myalgia syndrome. Clinical and pathologic features

Pulmonary involvement in the eosinophilia-myalgia syndrome

Phenylpropanolamine and the risk of hemorrhagic stroke

Fatal pulmonary arterial hypertension associated with phenylpropanolamine exposure

Pathology of pulmonary hypertension

The structure of the pulmonary trunk at different ages and in cases of pulmonary hypertension and pulmonary stenosis

Studies on the structure of the pulmonary trunk. I. Normal changes in the elastic configuration of the human pulmonary trunk at different ages

Medial mucoid lesions of the pulmonary artery in cystic fibrosis, pulmonary hypertension, and other disorders

The relation of age and blood pressure to atheroma in the pulmonary arteries and thoracic aorta in congenital heart disease

Pulmonary artery atherosclerosis. Correlation with systemic atherosclerosis and hypertensive pulmonary vascular disease

Vanek I Fibrous bands and networks of postembolic origin in the pulmonary arteries

Hypoxic pulmonary hypertension

Mooi WI Biopsy pathology of the pulmonary vasculature

Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth

Survival in patients with primary pulmonary hypertension. Results from a national prospective registry

Rubin LI Primary pulmonary hypertension

The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group

Annual report of the U.S. scientific registry of transplant recipients and the organ procurement and transplantation network. Bethesda, MD: U.S. Dept. of Health and Human Services, Health Resources and Services Administration, Bureau of Health Resources Development

Recovery from pulmonary hypertension with steroid therapy in a patient with Sjogren's syndrome and polymyositis

Regression of HIV-associated pulmonary arterial hypertension and longterm survival during antiretroviral therapy

Role of human immunodeficiency virus in primary pulmonary hypertension-case reports

Aneurysm of the pulmonary artery: review of the literature and report of a case

Aneurysms of the pulmonary arteries

Multiple pulmonary artery aneurysms

Mycotic aneurysm of the pulmonary artery: a report of 2 cases

Pulmonary arterial aneurysms. A pathological study of five cases

Pulmonary artery aneurysm with dissection after Blalock operation for tetralogy of Fallot

Mycotic aneurysms of the pulmonary arteries in intravenous drug addicts: report of three cases and review of the literature

Aneurysm of the pulmonary trunk un associated with intracardiac or great vessel leftto-right shunting

Dissecting aneurysm of the pulmonary artery with pulmonary hypertension

Aneurysm of the pulmonary artery: a review of the literature and report of 2 new cases

Aneurysm of the main pulmonary artery. Association with patent ductus arteriosus and ostium secundum defect

Aneurysm of the pulmonary artery with patent ductus arteriosus (Botallo's duct)

Dissecting aneurysm of the pulmonary trunk

Cystic medionecrosis of the pulmonary arteries

Marfan's syndrome: observations at necropsy with special reference to medionecrosis of the great vessels

Bunning Al Simultaneous aortic and pulmonary artery aneurysms due to giant cell arteritis

Multiple pulmonary artery aneurysms in Behcet's disease and Hughes-Stovin syndrome

Bilateral pulmonary artery aneurysm in Behcet syndrome: report of two operative cases

Segmental pulmonary artery aneurysms with peripheral venous thrombosis

The syndrome of pulmonary artery aneurysms, pulmonary artery thrombi, and peripheral venous thrombi

Is Hughes-Stovin syndrome Beh<;et's disease?

Traumatic aneurysm of the pulmonary artery

Embolotherapy in the bronchial and pulmonary circulations

Pulmonary embolism

Pulmonary Vascular Disease 157. Goldhaber SZ. Pulmonary embolism

The spectrum of pulmonary embolism

Pulmonary embolism: a new look at an old problem

Frequency of pulmonary thromboembolism in man

Havig 0. Deep vein thrombosis and pulmonary embolism

The post-mortem incidence of pulmonary embolism in a hospital population

Fatal pulmonary emboli in hospitalized patients. An autopsy study

The diagnostic approach to acute venous thromboembolism

Complications of right heart catheterization. A prospective autopsy study

The clinical features of sub massive and massive pulmonary emboli

D-dimer for the exclusion of acute venous thrombosis and pulmonary embolism: a systematic review

D-Dimer in venous thromboembolism

Pathology of pulmonary thromboembolism

Embolic pulmonary hypertension

Thromboembolic pulmonary arterial necrosis and arteritis in man

Ischemic disease of the myocardium and its complications

Pulmonary arterial bands and webs: an unrecognized manifestation of organized pulmonary emboli

Histologische Altersbestimmung von Thrombosen und Embolien

Healed pulmonary infarcts

The bronchial arteries. II. Their role in pulmonary embolism and infarction

Factors associated with pulmonary infarction

Pulmonary embolism, pulmonary hemorrhage and pulmonary infarction

Correlation of postmortem chest teleroentgenograms with autopsy findings

Pulmonary cavitation following pulmonary infarction

Septic pulmonary emboli

Septic pulmonary emboli: CT-radiographic correlation

Cavitating lung infarction after bland pulmonary thromboembolism in patients with the adult respiratory distress syndrome

Surgically treated unsuspected pulmonary infarction

Report of a case successfully treated by thromboendarterectomy, and a review of the literature

Chronic thromboembolic pulmonary hypertension

Pulmonary hypertension from chronic pulmonary thromboembolism

Chronic thromboembolic pulmonary hypertension

Chronic, massive thrombotic obstruction of the pulmonary arteries. Analysis of four operated cases

Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism

Massive thrombotic occlusion of the large pulmonary arteries

Case records of the Massachusetts General Hospital. Case 38-1981

Thromboendarterectomy for chronic, major-vessel thromboembolic pulmonary hypertension

Long-term outcome after pulmonary thromboendarterectomy

Chronic thromboembolic pulmonary hypertension-not so rare after all

Unilateral pulmonary artery thrombotic occlusion: is distal arteriopathy a consequence?

Surgical pathology of pulmonary thromboendarterectomy: a study of 54 cases from

Pulmonary vascular occlusion and fibrosing mediastinitis

Fibrosing mediastinitis. Causing pulmonary artery and vein obstruction with hemoptysis

Pulmonary vascular lesions occurring in patients with chronic major vessel thromboembolic pulmonary hypertension

Unrecognized emboli to the lungs with subsequent cor pulmonale

The clinical course of pulmonary embolism

Late prognosis of acute pulmonary embolism

The acute chest syndrome of sickle cell disease

Pulmonary complications of sickle cell anemia. A need for increased recognition, treatment, and research

Pathogenesis of lung disease in sickle hemoglobinopathies

Pulmonary aspects of sickle cell disease

Bacterial infection and sickle cell anemia. An analysis of 250 infections in 166 patients and a review of the literature

Pneumonia and pulmonary infarction in sickle cell anemia

The morbidity of sickle cell trait. A review of the literature

Pulmonary infarction in sickle cell trait

Acute chest syndrome in sickle-cell disease

Causes and outcomes of the acute chest syndrome in sickle cell disease

Bone marrow and fat embolism in sickle cell anemia and sickle cell-hemoglobin C disease

Pulmonary edema. Complication in the management of sickle cell pain crisis

Sickle cell chronic lung disease: prior morbidity and the risk of pulmonary failure

Pulmonary hypertension and cor pulmonale in the sickle hemoglobinopathies

Pulmonary hypertension as a risk factor for death in patients with sickle cell disease

Sudden death in a young woman with sickle cell anemia

The lung in sickle cell disease

Pulmonary thrombotic arteriopathy in patients with sickle cell disease

Pulmonary changes in sickle cell disease

Successful pulmonary thromboendarterectomy in two patients with sickle cell disease

Pulmonary hypertension in sickle cell hemoglobinopathy: a clinicopathologic study of 20 cases

Case records of the Massachusetts General Hospital. Case 52-1983

Report of two cases with numerous disseminated occlusions of the small pulmonary arteries

Case records of the Massachusetts General Hospital. Case 34-1997

Pulmonary bone marrow embolism in sickle cell disease

Bronchoalveolar lavage in adult sickle cell patients with acute chest syndrome: value for diagnostic assessment of fat embolism

Bronchopulmonary anastomoses in sickle-cell anaemia

Blockade of adhesion of sickle cells to endothelium by monoclonal antibodies

Endothelin-l production during the acute chest syndrome in sickle cell disease

Nonthrombotic pulmonary emboli

Pulmonary bone marrow embolism

Bone marrow embolism

Widespread bone marrow embolism with myocardial involvement

Fatal bone marrow pulmonary emboli in multiple myeloma

Incidence of bone marrow embolism due to closed-chest cardiac massage

Pulmonary bone marrow emboli in patients receiving external cardiac massage

Bone fragment emboli in the lungs of patients undergoing bone marrow transplantation

Evaluation of pulmonary megakaryocytes

Sis sons M, Hasleton PS. Quantitation of pulmonary megakaryocytes and fibrin thrombi from patients dying from burns

Pulmonary emboli caused by liver tissue

Myocardium as emboli in the systemic and pulmonary circulation

Brain tissue pulmonary emboli

Emboli of cerebral tissue in the lungs following severe head injury

Embolism of cerebral tissue to lungs

Massive pulmonary embolization by cerebral cortical tissue

Pulmonary skin embolism: a case report

Pulmonary tumor embolism

Pulmonary tumor embolism to alveolar septal capillaries

Microscopic pulmonary tumor emboli associated with dyspnea

Pulmonary tumor thrombotic microangiopathy with pulmonary hypertension

The fate of carcinoma emboli in the lung

Histological and experimental observations on the destruction of tumour cells in the blood vessels

Case records of the Massachusetts General Hospital. Case 13-2002

Pulmonary tumor thrombotic microangiopathy

Microscopic pulmonary tumor embolism causing subacute cor pulmonale: a difficult antemortem diagnosis

Subacute cor pulmonale

Incidence and clinical significance of tumor embolization to the lungs

Massive pulmonary embolism associated with a right ventricular myxoma

Fat embolism in Korean battle casualties: its incidence, clinical significance and pathologic aspects

The significance and classification of fat embolism

Posttraumatic fat embolism. Its clinical and subclinical presentations

A clinicopathologic study of fourteen cases of amniotic fluid embolism

Amniotic fluid embolism

Embolism to the lungs by trophoblast

Syncytial trophoblastic embolism associated with placenta increta and preeclampsia

Maternal death due to pulmonary embolism of trophoblastic cells

Subacute cor pulmonale following trophoblastic pulmonary emboli

Sudden death from trophoblastic embolism in pregnancy

The occurrence of decidual tissue within the lung: report of a case

Rupture of the basal (decidual) plate in abruptio placentae: a pathway of auto extraction from the decidua into the maternal circulation

Pleuropulmonary endometriosis and pulmonary ectopic deciduosis: a clinicopathologic and immunohistochemical study of 10 cases with emphasis on diagnostic pitfalls

Fiber embolization: a hazard of cardiac surgery and catheterization

Pulmonary fiber embolism and granuloma

The impact of substance abuse on the respiratory system

The pulmonary vascular lesions of intravenous drug abuse

The pulmonary pathology of illicit drug and substance abuse

Crystal formation: a new complication of total parenteral nutrition

Pulmonary deposition of calcium phosphate crystals as a complication of home total parenteral nutrition

Fatal microvascular pulmonary emboli from precipitation of a total nutrient admixture solution

Pulmonary arterial lipid deposits in newborn infants receiving intravenous lipid infusion

Malassezia pulmonary vasculitis in an infant on long-term Intralipid therapy

Pulmonary cholesterol crystal embolization

Case records of the Massachusetts General Hospital. Case 11-1996

Complications of inferior vena cava filters

Teflon embolization of pulmonary arteries

Clinicopathologic review of pulmonary silicone embolism with special emphasis on the resultant histologic diversity in the lunga review of five cases

Silicone fluid-induced pulmonary embolism

Acute and latent pneumonitis after subcutaneous injections of silicone in transsexual men

Acute pneumonitis after subcutaneous injections of silicone in transsexual men

Mercury pulmonary emboli following intravenous self-injection

Elemental mercury embolism to the lung. Images in Clinical Medicine

Report of case associated with routine barium enema

Pulmonary bile emboli. Sequelae of iatrogenic trauma

Pulmonary fecal embolization complicating the Budd-Chiari syndrome

Pulmonary pathology

Longterm histopathologic follow-up of bronchial arteries after therapeutic embolization with polyvinyl alcohol (Ivalon) in patients with cystic fibrosis

Pulmonary dirofilariasis: the great imitator of primary or metastatic lung tumor. A clinicopathologic analysis of seven cases and a review of the literature

Pulmonary dirofilariasis: a clinicopathologic study of 41 lesions in 39 patients

Diagnostic pathology of parasitic infections with clinical correlations

Pathophysiology of pulmonary edema

Biology of disease. New insights into mechanisms of pulmonary edema

The pathogenesis of pulmonary edema

The pathophysiology of pulmonary edema

Pulmonary venous hypertension

Histological changes in the lung in diseases associated with pulmonary venous hypertension

Case records of the Massachusetts General Hospital. Case 17-1995

Pulmonary vein obstruction: an uncommon sequel to chronic fibrous mediastinitis

Multilobar pulmonary venous obstruction with pulmonary hypertension

Mitral stenosis in facsimile

Pulmonary venous and arterial hypertension due to chronic fibrous mediastinitis. Hemodynamics and pulmonary function

Unilateral pulmonary arteriosclerosis. Unusual fibrous connective tissue growth associated: review of literature and discussion of possible physiological mechanisms involved in these changes

Correlation of pulmonary arteriolar resistance with pulmonary vascular changes in patients with mitral stenosis before and after valvulotomy

The pulmonary vessels in mitral stenosis

Extreme pulmonary hypertension caused by mitral valve disease: natural history and results of surgery

disease. Philadelphia: WB Saunders

Pulmonary function in mitral stenosis

Pulmonary fibrosis in rheumatic heart disease

The nature and significance of the structural changes in the lungs in mitral stenosis

Pulmonary capillary hemangiomatosis: a unique feature of congestive vasculopathy associated with hypertrophic cardiomyopathy

Pulmonary hemosiderosis in mitral stenosis

The relation of pulmonary haemosiderosis to hypertension in the pulmonary arteries and veins in mitral stenosis and congenital heart disease

Pulmonary Vascular Disease

Mitral stenosis with exertional cyanosis and pulmonary hemosiderosis

Iron incrustation of the pulmonary vessels in patent ductus arteriosus with congenital mitral disease

Mineralizing pulmonary elastosis in chronic cardiac failure

Pathology of the lungs in mitral stenosis in relation to respiratory function and pulmonary haemodynamics

Mitral stenosis and pulmonary arteriosclerosis. Correlation of pulmonary arteriosclerosis, right ventricular hypertrophy, and thromboembolism in autopsied patients who died with mitral stenosis

The relation between left atrial hypertension and lymphatic distension in lung biopsies

Pulmonary veno-occlusive disease

Pulmonary veno-occlusive disease

Pulmonary veno-occlusive disease

Pulmonary veno-occlusive disease. A report of four cases

Pulmonary venoocclusive disease

Uncommon tumors

Bredin CPO Pulmonary venoocclusive disease presenting as sudden death

Pulmonary veno-occlusive disease as a cause of sudden infant death

Vascular toxicity associated with chemotherapy and hormonotherapy

Malignancyassociated pulmonary veno-occlusive disease: report of a case following autologous bone marrow transplantation and review

Pulmonary venoocclusive disease in pregnancy

Pulmonary veno-occlusive disease in siblings: case report and morphometric study

Pulmonary veno-occlusive disease. Involvement of pulmonary arteries and review of the literature

Massive pulmonary edema and death after prostacyclin infusion in a 1085 patient with pulmonary veno-occlusive disease

A case of pulmonary veno-occlusive disease responding to treatment with azathioprine

Pulmonary veno-occlusive disease: case report and review of the literature

Spijker 1. Capillary haemangiomatosis of the lung

Pulmonary capillary hemangiomatosis: a report of three cases and a review of the literature

Pulmonary capillary hemangiomatosis

Congenital pulmonary capillary hemangiomatosis: report of two cases and review of the literature

Familial pulmonary capillary hemangiomatosis resulting in primary pulmonary hypertension

Treatment of pulmonary capillary hemangiomatosis with recombinant interferon alpha-2a

Pulmonary capillary hemangiomatosis-like foci. An autopsy study of 8 cases

Pulmonary capillary hemangiomatosis associated with primary pulmonary hypertension

An autopsy case of pulmonary capillary hemangiomatosis without evidence of pulmonary hypertension

De novo pulmonary capillary hemangiomatosis occurring rapidly after bilateral lung transplantation

Hypoxia on the pulmonary circulation. How and where in acts

Pulmonary vasoconstriction in response to precapillary hypoxemia

Hypertensive pulmonary vascular disease in state of chronic hypoxia

Arias-Stella 1. Pulmonary hypertension and pathology at high altitudes

Chronic mountain sickness

Lack of smooth muscle in the small pulmonary arteries of the native Ladakhi. Is the Himalayan highlander adapted?

High altitude disease

Sleep apnea syndromes

The occurrence of sleep-disordered breathing among middle-aged adults

Sleep apnea-a major public health problem

Obstructive sleep apnea. Implications for cardiac and vascular disease

Cardiopulmonary consequences of obstructive sleep apnea

A peculiar type of cardiopulmonary failure associated with obesity

Heart failure due to extreme obesity

Reversible cardiopulmonary syndrome with extreme obesity

Heart failure due to extreme obesity

Extreme obesity associated with alveolar hypoventilation-a Pickwick ian syndrome

De subitaneis mortibus. III. Pickwick ian syndrome

Day-night pattern of sudden death in obstructive sleep apnea

Pulmonary hypertension and hypoxemia in obstructive sleep apnea syndrome

Pulmonary artery hypertension and sleep-disordered breathing: ACCP evidence-based clinical practice guidelines

Pulmonary hypertension in patients with obstructive sleep apnea syndrome

Pulmonary arterial hypertension in patients with sleep apnoea syndrome

Echocardiographic features of the right heart in sleep-disordered breathing

Heart failure of the hunchback

disease. Philadelphia: WB Saunders

A study of the pulmonary vascular bed

Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension

The effect of continued hypoxia on rat pulmonary arterial circulation. An ultrastructural study

New findings in pulmonary arteries of rats with hypoxia-induced pulmonary hypertension

Changes in the pulmonary arteries of the rat during recovery from hypoxia-induced pulmonary hypertension

Structural basis of hypoxic pulmonary hypertension: the modifying effect of chronic hypercapnia

Hypoxia induces type II NOS gene expression in pulmonary artery endothelial cells via HIF-1

Temporal, spatial, and oxygen-regulated expression of hypoxia-inducible factor-1 in the lung

Studies on the structure of the pulmonary trunk II. The evolution of the elastic configuration of the pulmonary trunk in people native to high altitudes

Studies on the structure of the pulmonary trunk. III. The thickness of the media of the pulmonary trunk and ascending aorta in high altitude natives

Hypoxemia and pulmonary hypertension

Cardiopulmonary pathology in patients with sleep apnea/ obesity hypoventilation syndrome

The terminal portion of the pulmonary arterial tree in people native to high altitudes

Pulmonary vascular changes with chronic unilateral pulmonary hypoxia

Pulmonary veins in highaltitude residents: a morphometric study

Effect of scoliosis on growth of alveoli and pulmonary arteries and on right ventricle

Post-mortem size and structure of the human carotid body. Its relation to pulmonary disease and cardiac hypertrophy

Carotid body hypertrophy in patients with cystic fibrosis and cyanotic congenital heart disease

High altitude hypoxia and chemodectomas

Pulmonary hypertension in the interstitial lung diseases

Pulmonary vascular disease in honeycomb lung

Pulmonary hypertension in interstitial lung disease: relation of vascular resistance to abnormal lung structure

Pulmonary pathology of the acute respiratory distress syndrome

Acute respiratory distress syndrome

The pulmonary vascular lesions of the adult respiratory distress syndrome

Pulmonary hypertension in severe acute respiratory failure

Early bedside detection of pulmonary vascular occlusion during acute respiratory failure

Morphometry of parenchymal and vascular alterations in ARDS after extracorporeal carbon dioxide removal therapy (ECC02-R-therapy)

A pathophysiological study of 10 cases of hypoxic cor pulmonale

Severe pulmonary hypertension and chronic obstructive pulmonary disease

The small pulmonary arteries in emphysema

Small pulmonary vessels in advanced pulmonary emphysema

Pulmonary vascular structure and function in chronic obstructive pulmonary disease

Morphologic changes in the muscular pulmonary arteries: relationship to cigarette smoking, airway disease, and emphysema

An assessment of the anatomical factor in cor pulmonale in emphysema

Morphometric study in chronic obstructive bronchopulmonary disease

The bronchopulmonary venous collateral circulation with special reference to emphysema

Acknowledgments. The authors acknowledge the contribution of Dr. c.A. Wagenvoort, who wrote the chapters on pulmonary vascular disease in the first two editions of this text. His lucid morphologic descriptions of pulmonary vascular remodeling have influenced and benefited pathologists for over 40 years, and have been integrated into this edition.The authors also thank Diane Gillihan for expert secretarial help, Vince Messina for photographic support, and the staff of the Brittingham Memorial Library for bibliographic assistance.